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Abstract 
This study exatnined patterns of psychotropic medication use among 120 participants with 
intellectual disabilities (ID) who used to live in facilities and now reside in community-based 
settings in Ontario. There were significantly more participants taking psychotropic medication in the 
community (83.30/0) than in the facility (74.2%). Of those who showed change, 4.2% were taking 
medication in the facility but not in the community, and 13.3% were taking medications in the 
community but not in the facility. While significantly more participants in the community were 
taking antipsychotic and antidepressant medications, there was no significant increase in psychiatric 
diagnoses after relocation. Additionally, PRN use was significantly reduced in the comlnunity while 
daily medication use was significantly higher. The most common PRN in both settings was 
lorazepam and the most common antipsychotics were risperidone, quetiapine and olanzapine. 
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Introduction 
Ontario has a long history of institutional care for people with intellectual disabilities (lD) 
dating back to the late 1800s. The deinstitutionalization moven1ent began in Ontario in the late 
1960s. The final wave of closures was announced in the fall of 2004. The last facility] closed in 
April of 2009 (Lemay, 2009). Research into the outcomes of this process is vital to ensuring that it 
has lead to positive outcomes for persons with ID. The goal of deinstitutionalization is to allow 
people to be part of their communities and to enjoy an improved quality of life (Emerson & Hatton, 
1996). Over 40 years of research have been conducted regarding the in1pact of deinstitutionalization 
in areas such as quality of life (Kozoma, Mansell & Beadle-Brown, 2009); health (Kozoma et aI., 
2009); mortality (Cooper & Picton, 2000); staff contact (Young et aI. 1998), community 
participation (Cummings, 1990) parent involvement (Young et aI. 1998), meaningful activity 
(Emerson & Hatton, 1996); and challenging behaviour (Golding, Emerson & Thornton, 2005). 
However, few studies have looked at psychotropic medication use across and within psychotropic 
medication classes among individuals who have resided in an institution and thereafter transitioned 
into a community-based setting (Nottestad & Linaker, 2003; McGillivray & McCabe, 2005; Thinn, 
Clarke, & Corbett, 1990) including very little examination of Canadian samples (Gowdey, Zarfas & 
Phipps, 1987). 
The purpose of this study is to closely examine patterns of psychotropic medication changes, 
that may be associated with relocation from an institution into a community setting in Canada. 
I For the purposes of this paper the word facilities and institutions will be used interchangeably. 
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Literature Review 
History of Deinstitutionalization 
During the 1920s - 1940s, individuals with ID were seen as inferior citizens who did not 
have rights and dignities (Wehmeyer & Patton, 2000). These notions propagated the amount of 
individuals referred to an institution setting. Large congregate settings (institutions) were built to 
segregate individuals who were born with an ID (Kugel & W olfensberger, 1969). The development 
of institutions seemed to adequately solve this problem by housing individuals with ID who were 
seen as the 'disenfranchised of society' (Kugel & Wolfensberger, 1969). These institutions were 
built far from community settings; they were custodial instead of rehabilitative in nature and were 
primarily based upon a medical model of care. Since the 1960s, concenlS have been raised about 
the standards of care (i.e., overcrowding, understaffing and underfinancing) for those living in these 
settings (Kugel & Wolfensberger, 1969). Kugel and W olfensberger (1969) believed that to 
improve the standards of care, it was not only necessary to rectify these problems in the institution, 
but to also develop a community-based setting for individuals with ID, as integration was of 
paramount importance. The President's Committee on Mental Retardation was commissioned, in 
the U.S. to review the condition of the institutionalized environment in 1967 (Kugel & 
W olfensberger, 1969). The result of this review recOlnmended a moved towards 
de institutionalization. 
Shift to Community Living 
In addition to the report commissioned by the President's Committee On Mental Retardation 
there were silnilar movements happening in other parts of the world (Kugel & Wolfensberger, 
1969), some of which had successful programs already implemented (i.e. Scandinavia) that 
challenged the notions about segregation. Positive changes started to occur in the legislature that 
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would lead to the provision of more support for individuals with ID (i.e. the Social Security Act, the 
Smith-Fess Act and the Fair Labor Standards Act) and by the 1960s - 1970s, talk of the unethical 
nature of the institutionalized environment became more prevalent. This, in conjunction with the 
concept of normalization, gave way to deinstitutionalization. Normalization refers to where "the 
mentally retarded should obtain an existence as close to normal as possible" (Kugel & 
Wolfensberger, 1969, p. 79) or "the utilization of culturally valued means in order to establish 
and/or maintain personal behaviors, experiences, and characteristics that are culturally normative or 
valued" (Wehmeyer & Paton, 2000, p.140). Hence, it emphasized that individuals with ID should 
be included and be able to live in a community-based environment, as opposed to, a segregated 
congregate setting outside of the c'ommunity (Hamelin, Frijters, Griffiths, Condillac & Owen, 
2011). An individual with ID also has the right to least restrictive environments, a choice in the 
matter of their personal care, access to loved ones and access to affordable housing. These concepts 
apply to all individuals regardless of their intellectual functioning. Advocating for these rights gave 
way to the development of community-based placements and a supported living environment 
(Hamelin et ai., 2011). 
In theory, the thought of community living encouraged individuals with ID to enjoy the 
same freedoms as individuals living in the community (Mansell, 2010). However, there was 
understandably much resistance from families regarding moving individuals with ID into a 
community setting. Sonle concerns reported in the literature (Tabatabainia, 2003) included a fear 
that the community placement may not support their relatives as well as an institutional environment 
would, possibly leading to regression of skills. There was a fear that the community placement 
would not provide a safe, sound, long-term place to reside in like the institution environment 
seemed to. There were concerns about staffing, mistrust of the governnlent and trust in the 
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professional who initially lead them into thinking that the institutional environment was the best 
place for their children with ID to reside. For the deinstitutionalization process to be successful, it 
was necessary that the families of the transitioning individuals support the general 
deinstitutionalization movement (Tabatabainia, 2003). The initial negative perception that fanlilies 
displayed, helped shape the deinstitutionalization process by engaging the advocates of 
deinstitutionalization in answering some difficult questions about the overall procedure, namely, are 
outcomes in the community indeed better than in the institutional environment (Tabatabainia, 2003). 
Setting up community placements appropriate for the diversity of individuals leaving the 
institutionalized setting proved to be difficult, as careful consideration is required for placement 
even for the individuals ,with less complex needs. For those with complex needs, it provided a 
challenge to the community to provide a placement suitable to their complexities (Mansell, 2010). 
Person-centered planning was a critical component to the deinstitutionalization planning and 
placement process. Person-centered planning consists of attention to the unique needs of the 
individual. Person-centered planning also looks to the individuals' strengths and inspirations as 
indicators for placements, as opposed to their risks or deficits. Secondly, and most important, this 
model seeks to utilize the individuals' family and support network as a resource. And lastly, it 
strives to achieve the goals set out by the individual, instead of working within the limitations of the 
system (Mansell & Beadle-Brown, 2004). 
It is reported that individuals with less complexities were among the first to transition to the 
community, thereby leaving those with severe needs residing in the institution to transition last. 
Integrating individuals with severe needs (i.e. those with multiple diagnoses, physical disabilities 
and/or severe social iInpairments) back into COnllTIUnity settings carne with a variety of challenges 
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(Mansell, 2010). However, as mentioned above, research conducted has shown that there are 
positive benefits to living in community settings, regardless of the level of individualized need. 
Research Conducted on the Outcomes of Deinstitutionalization 
5 
Researchers have been actively examining changes that have resulted from relocating from 
an institution to a community setting for people with ID. For example, extensive research has been 
conducted on adaptive behaviour outcomes (e.g., Hamelin et ai., 2011; Joel & Betsy, 1983; Paul, 
Hall & Tameeka, 2005; Young, 2006) staff contact (Emerson & Hatton, 1996) and changes in 
challenging behaviour (Bhaumik et aI., 2009; Golding, Emerson, & Thornton, 2005; Kim., Larson, 
& Lakin 2001; Kim et ai., 2001). Research has also been conducted on making choices (Emerson & 
Hatton, 1996; Young & .Ashman, 2004); engagement of meaningful activity and community 
participation (Emerson & Hatton, 1996; Mansell, Elliott, Beadle-Brown, Ashman, & Macdonald, 
2002); contact with family and friends (Emerson & Hatton, 1996; Lamb, 1998; Molony, & Taplin, 
1988); health, mortality and quality of life (Cooper & Picton 2000). Limited research has also been 
conducted regarding changes in Inedication use (Kozoma et ai., 2009). 
Generally speaking, results in most of the abovementioned areas have shown positive 
improvements regarding individuals resettling into community-based placenlents. Results regarding 
adaptive behaviour (personal competence) have generally shown positive improvements in 
individuals who have moved from institution-type settings to community-based settings. According 
to a review published in the UK during the 1990s which looked at 26 studies regarding adaptive 
behaviour (Emerson & Hatton, 1996), 67% of the research showed a positive improvement, while 
33% showed no difference. However, only a few studies in their sample included longitudinal 
analyses. A plateau effect is seen in these select studies, with measures taken over a long duration 
of time where there is a significant increase in adaptive skills upon the Inove to the comillunity but 
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then few additional gains are made after participants reside in the community setting over time. 
Another study by Hamelin et aI, (2011) reviewed 23 studies and reported that "moderate habilitative 
gains" were seen in 75% of the adaptive behaviour domains. Young (2006) also looked at adaptive 
behaviour across twelve and twenty-four months after relocation with a sample of individuals in the 
moderate and severe cognitive ranges. In this study he compared a community setting to a cluster 
setting and found that the community setting yielded higher results, but that adaptive behaviour 
improved for both. 
Making choices is a necessary step in personal development and independence. Research 
consistently shows that a smaller, community-based setting is related to more opportunities for 
choice making and self-determination than large congregate settings (Kozma et aI., 2009). 
Researchers emphasize that it is not the change of setting that guarantees outcomes but rather what 
occurs in that setting (Kozma et aI., 2009). Young and Ashman (2004) conducted a repeated 
measures study in which all participants were followed for one, six, twelve, eighteen and twenty-
four months during community living. Community placements were shown to increase the 
opportunities for choice making. Emerson and Hatton's (1996) review of 12 studies found sinlilar 
results although Young and Ashman (2004) noted that there is a difference between choice over 
daily decisions (which is high in community-based settings) versus choice over broader aspects of 
their lives. The latter of which is less available to individuals with ID. 
Quality of life, also used to measure relocation outcomes, may refer to things like 
interpersonal relations, social inclusion, personal development, physical well-being, self-
determination, material well-being, emotional well-being, rights, family, recreation, leisure, safety 
and security (Kozma et aI., 2009). In most studies, relocation to the community has been associated 
with a better quality of life (Cooper & Picton, 2000; Kozoma et aI., 2009; Young, 2004). 
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Community participation, meaningful engagement and relationships are another area of 
research commonly conducted during the deinstitutionalization era. The study of community 
participation and meaningful engagement is important because often large atll0unts of time pass 
where there are no activities, resulting in boredom, isolation and inactivity. This may also be 
attributed to improper planning by staff (Mansell et aI., 2002). An Australian study found 
improvements in daily variation, normalized lifestyle and community interaction when looking at 85 
young adults with severe mental retardation after four years of relocation (Cummings, 1990). A 
review of 13 Australian studies found an improveillent in comillunity participation and improved 
contact with fanlily and friends (Young, Sigafoos, Suttie, Ashlnan, & Grevell, 1998). Another study 
found significant improvements iri community participation and social-interpersonal relationships 
and that community participation was related to (a) goals set for the individual in care, (b) adaptive 
behaviour and (c) complexity of needs (Baker, 2007; Kozma et aI., 2009). Also, family contacts 
tended to be re-established and maintained in the community-based settings over tinle (Kozma et aI., 
2009). 
In respect to health and mortality, studies have shown that there may be little or no change 
with respects to individuals who have relocated (Young et aI., 1998). While researchers have found 
that there is no evidence of trauma related to the transition of relocation, there do seem to be higher 
rates of mortality shortly after relocation. Looking into the 'health' of individuals with ID post 
relocations should take into account a variety of issues. For example, less restrictive living 
arrangements are associated with obesity, smoking and poor diet and cOlllmunity living opens up the 
possibilities of crime involvement and / or exposure to abuse (Kozma et aI., 2009). 
Staff interaction with individuals in community-based settings has received a lot of attention. 
For example, Emerson and Hatton (1996) reviewed 26 studies associated with staff contact and their 
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findings showed that the amount of time participants received contact from staff was 3-16% in 
hospitals but 5-31 % in staffed houses. While the amount of time participants received contact from 
staff increased in staffed houses, it is still very low. Note that in the study by Emerson and Hatton 
(1996) they do not include' staff engagement' as a part of' staff contact'. Staff engagement is a 
separate area. Staff engagement (time participants spend doing non-social activities and/or social 
interaction) is reported in a range between 2-23% for hospitals and 8-74% for staffed houses. The 
studies on staff interaction reviewed were published earlier (1980s-1990s) and it is likely many 
changes have occurred since then. More recent studies show, as well, that post relocation, staff 
contact increased and then increased again at a follow up time, when individuals were placed for at 
least nine months (Golding et aI., 2005). 
While research shows favourable findings when investigating the above-mentioned areas, 
there are more varied findings when looking at the decrease of aggression in community-based 
settings (Bhaumik et aI. 2009; McGillivray & McCabe, 2005). It is reported that between 5 to 15% 
of adults with ID show challenging behaviours (Robertson, Emerson, Pinkeney, et aI. 2005). 
Individuals that are characterized as having cOlnp1ex support needs may exhibit challenging 
behaviour, multiple diagnoses, comorbid psychiatric problems, possess physical disabilities, are 
non-verbal, and have limited capability to develop social relationships (Mansell, 2010; Robertson et 
aI., 2004). These complexities require even more careful planning to find a highly suitable 
placement and therefore, attention needs to be given to this sub-population of individuals. Despite 
complex behaviour, there are supports available in the community that can be accessed and 
maintained to provide support to individuals with ID. A study conducted in the UK, which assessed 
challenging behaviour before and after relocation, has found that supports in conlmunity-based 
settings have led to a decrease in the observed occurrences of challenging behaviour (Golding et aI., 
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2005). Kim et aI, (2001) conducted a review of behavioural outcomes of deinstitutionalization 
between 1980 and 1999. Their results show that ten longitudinal US studies found improvements in 
challenging behaviour after relocation, including a study reporting up to seventy-two lllonths of 
results. In contrast, six studies (with two of these studies reporting on results at up to twenty-four 
months) reported increased levels of challenging behaviour (Kim et aI., 2001). Other studies 
published in Norway also suggest an increase in challenging behavior shortly after 
de institutionalization (Nottestad & Linaker, 2001; Nottestad & Linaker, 2002). Golding et aI, 
(2005) report that some studies show that no change is found when some individuals move settings. 
However, there may be a flaw in the method used to measure the occurrences of challenging 
behaviour because standardized rating scales tend to show no change whereas direct observation 
methods lllay be more sensitive to change. In many of the studies reviewed assessment tools, rather 
than direct observations, were used. 
An area that is understudied in the literature is the use of psychotropic medication among 
individuals who have relocated as part of deinstitutionalization. For example, a systematic review 
conducted by Kozma et aI, (2009) looked at 68 studies regarding outcomes in the different 
residential settings. The purpose of this study was to review findings that had emerged regarding 
deinstitutionalization. The 68 studies could be grouped into 10 categories: (1) community presence 
and participation, (2) social networks and friendships, (3) family contact, (4) self-determination and 
choice, (5) quality of life, (6) adaptive behaviour, (7) user and family views and satisfaction of 
family members, (8) health, risk factors and mortality, (9) challenging behaviour and (10) 
psychotropic medication. Out of these 68 studies, only 4 studies looked at the use of psychotropic 
medication and the results are inconclusive because some researchers have found a decrease in 
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medication use after relocation, some have found insignificant changes, and some have found an 
increase in medication use (KoZlTIa et aI., 2009). 
Psychotropic Medication 
10 
Individuals with ID comlTIonly exhibit behavioural disturbances (i.e. aggression, self-
injurious behaviour, property destruction), and elTIotional and psychiatric disturbances that make 
them among the most medicated group (Bradley & Summers, 1999; Holder & Gitlesen, 2004). 
Even though psychotropic medication is employed as a treatment option, there is still much concern 
about its usage (Unwin & Deb, 2011). For example, the literature shows that psychotropic 
medication is effective i,n treating 'mental health diagnoses in individuals with ID, however, in some 
cases there are concerns about the efficacy of psychotropic agents used to treat challenging 
behaviour (Chapman, Gledhill, Jones, Burton & Soni, 2006), especially without a psychiatric 
diagnosis (Young & Hawkins, 2002). There is also evidence to suggest that individuals with ID are 
often over-medicated and undertreated (Bradley & Summers, 1999). Psychotropic medication may 
have severe side effects (e.g., tardive dyskinesia, weight gain etc.) and therefore should be 
prescribed with caution (Unwin & Deb, 2011). Individuals with ID are often given more than one 
medication for the same symptom (sometimes called polypharmacy) thereby exposing them to side 
effects frOlTI multiple drugs and a risk that drug interaction n1ay be an additional long term negative 
effect (Mahan et aI. 2010; Rinck, Guidry & Calkins, 1989;). Studies such as the one conducted by 
F odstad et aI. (2010) aim to assess if the side-effects of the psychotropic medication truly outweigh 
its therapeutic benefits. 
A large percentage of individuals with ID are prescribed psychotropic medications for the 
management of challenging behaviours (Matson & Neal, 2008). With the development of 
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institutions, many individuals who exhibited challenging behaviours were also commonly placed in 
an institution and therefore likely taking some sort of psychotropic medication (Mathson & Neal, 
2008). As a result, the use of psychotropic medication in residential facilities has become a research 
focus (Briggs, 1989; Findholt & Emmett, 1990; Fischbacher, 1987; Fodstad et aI., 2010; Poindexter, 
1989; Robertson, Emerson, Gregory, et aI. 2000; Silva, 1979). Research shows that up to 50% of 
individuals residing in institutions are taking psychotropic medications (Rinck et aI., 1989). 
Brandford (1996) reported that there was a prescribing prevalence of23% of individuals living in 
Leicestershire (44% of those in the hospital, 19% in the community and 9% in families home). In 
Brandford (1997), it was suggested that antipsychotic medications were used for 30-50% of 
individuals living in institutions, 20-30% of those living in the community and 100/0 of those living 
at home with relatives. 
- With the closing of institutions, the responsibility of providing medical and social services 
became the responsibility of the conlmunity (Lannon & Vaughn, 2000). Therefore, studies have 
focused on truly assessing if community-based placements were in fact more beneficial than 
institutional environments. Studies have looked at medication use in conlmunity settings for 
individuals who have been relocated (Aman & Field & Bridgman, 1985; Bisconer, Sine & Zhang, 
1996; Burd, et aI. 1991; Gowdey, Zarfas & Phipps; Holden & Gitlesen, 2004; Martin & Agran, 
1985; Zaharia & Struxness, 1991). 
Studies have included participants from both an institution-type setting and a community-
based setting (Clarke, Kelly, Thinn & Corbett, 2008; Harper & Wadsworth, 1993; Molyneux, 
Emerson & Caine, 1998; Robertson, Emerson, Gregory, Hatton, et aI. 2000; Branford, 1997). These 
studies, however, have methodological limitations due to their use of a cross-sectional design (i.e. 
collecting data regarding medication use frOlll participants living in different residential settings at 
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one point in time). Few studies have looked at psychotropic medication practices of individuals 
using a longitudinal design (i.e. looking at the same participants across time) (McGillivray & 
McCabe, 2005; Nottestad & Linaker, 2003; Thinn, Clarke, Corbett, 1990). Other studies have 
limitations in that they report on psychotropic medication use yet the focus of the study is really 
designed to look at challenging behaviour or psychiatric diagnoses and not psychotropic medication 
directly (Nottestad & Linaker 1999; Robertson, Emerson, Pinkney, Caesar, et ai. 2005). 
Medication use. 
There is an ill-informed belief that psychotropic medication effective for those with a 
psychiatric diagnosis will be equally effective for those who have an ID (Holder & Gitlesen, 2004). 
Studies show that in fact, not all individuals with ID prescribed psychotropic medication even had a 
psychiatric diagnosis. For example, in Holder and Gitlesen (2004) only 54% of the population 
prescribed psychotropic medication had a psychiatric diagnosis and only 31.3% prescribed an 
antidepressant had depression. In the same study 53% percent of individuals were prescribed 
psychotropic medications due to a behavioural probleln. These findings are corroborated by other 
researchers, such as Clarke, Kelly, Thinn, and Corbett (1990) who found that 83.7% of individuals 
with a psychiatric diagnosis were in fact receiving psychotropic medication. However, 36.2% of 
individuals without a recorded psychiatric diagnosis were also receiving medications. Other studies 
report that between 220/0 - 300/0 of individuals in an inpatient hospital received antipsychotics, where 
only about 4% of the population had a psychiatric diagnosis (Wressell et aI., 2011). These studies 
show that there is a discrepancy between the number of individuals taking psychotropic medications 
and the number of individuals diagnosed with a psychiatric diagnosis. 
A primary reason for this discrepancy is that many individuals with ID who are receiving 
psychotropic medications are receiving thenl as a way to treat challenging behaviours (Fleming, 
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Caine, Ahmed & Smith, 1996; McGillivray & McCabe, 2005; Robertson et aI., 2000). Molyneux 
and colleagues (1998) suggest that antipsychotics (neuroleptics) are readily prescribed for the use of 
challenging behaviour. Chapman et aI, (2006) report that more antipsychotics (36.7%) and 
antidepressants (230/0) were prescribed to deal with behaviour than were prescribed for mental 
health reasons (antipsychotics 18.4% and antidepressants 19.2 %). Fleming et aI, (1996) indicate 
that reasons for the delivery of antipsychotic medications include behaviour problems, agitation, 
aggression, anxiety, verbal aggression, self-injurious behaviour, institutional behaviour, and 
schizoid-like outbursts. Bhaulnik et aI, (2009) conducted a study of 51 participants all of whom had 
severe challenging behaviour. At baseline (six months prior to discharge), 67% of the participants 
were taking psychotropic drugs (for mental health and challenging behaviour). Post discharge, no 
changes were seen in the psychotropic drug use although 80% of participants' challenging 
behaviour improved. While this study shows that psychotropic medications can be effective, other 
researchers suggest that finding evidence to show the effectiveness of psychotropic medications 
when treating challenging behaviours is scarce (Oliver-Africano, Murphy & Tyrer, 2009; Tyrer et 
ai. 2008), especially using randon1ized controlled trials. Tyrer et al. 2008 conducted a three-arm, 
parallel-group praglnatic trial of a placebo, haloperidol and risperidone with balanced randomisation 
but no stratification, into each arm. Their results showed that there was noted regression with all 
treatn1ents after 4 weeks. The greatest decrease in aggression was in the placebo trial. There was 
no difference between groups regarding aberrant behaviour. Good evidence is lacking and 
inconsistent regarding antipsychotic medication use. Deb, Sohanpal, Soni, Lenotre and Unwin 
(2007) showed in their study, on the effectiveness of antipsychotic medication in managing problem 
behaviour, that there are two randon1ized controlled trial (RCT) studies. One with a sample 
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composed of adults and one with a sample composed of adults and children. These studies show that 
risperidone is effective but that there are risks such as adverse effects. 
Psychotropic medications can pose significant risks when used inappropriately because of 
the many adverse side effects associated with their use (Clarke et aI., 1990; Robertson et aI., 2000). 
Wressell and colleagues (2011) report on a study by Aman (1984) that shows chlopromazine as 
having adverse effects on learning performance. In another study done by Chapman et aI, (2006), 
23% of individuals were prescribed antimuscarinics to reduce the Parkinsonian side effects of the 
I 
anti-psychotic medication. Other negative side effects of medications include weight gain, 
i 
' I 
irritability, learning inhibition and possible toxicity. Other common adverse reactions include 
anticholinergic effects (i.e. blurred vision, constipation, dry mouth, urinary hesitance), 
extrapyramidal symptoms (restlessness), sedative effects, tardive dyskinesia (i.e. involuntary 
repetitive body movements) and dermatological reactions (Wehmeyer & Patton, 2000). 
When individuals are placed on Inedication it should be supervised by a consulting 
psychiatrist and reviewed by a multidisciplinary team. There should also be some effort to 
implement a behavioural-based program to decrease challenging behaviours as opposed to only 
changing or reviewing the medication when prompted by a significant change in behaviours or the 
appearance of side effects (Flelning et aI., 1996). A more proactive approach needs to be 
implemented to assist in utilizing medications in a way that is helpful not harmful to individuals 
with ID. Therefore, ongoing research needs to look at current prescribing practices and their 
relationship to past prescribing practices to assess if there is indeed change. These prescribing 
practices were among the unethical practices identified in institutional environments. Rates of 
prescribed antipsychotic nledication ranged between 25 - 50% of individuals living in an 
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institutionalized environment; 20 - 500/0 of individuals living in a community based setting; and, 
only 10% of people living with their natural or substitute family (Robertson et aI. , 2000). 
Polypharmacy. 
15 
Polypharmacy occurs when more than one medication is prescribed, although some authors 
use it to reflect more than one medication being prescribed to treat the same symptom(s) (Holden & 
Gitlesen, 2004). Zaharia and Struxness (1991, p. 192) define polypharmacy as the use of "multiple 
drugs within the same class". There is no agreed-upon definition of polypharmacy, but for the 
purposes of this thesis, studies that have included results regarding polypharmacy (regardless of the 
definition they have used) will be 'included in this review. 
Polypharmacy has been shown to be of a concern in both community and institutional 
settings. Many studies also report on co-pharmacy (multiple drugs from different classes), however 
not much is known about the side effects of these combinations of different drugs. Individuals can 
receive multiple psychoactive agents (Harper & Wadsworth, 1993) and multiple neuroleptics agents 
but research cautions against this given that these agents are not synergistic in their action. Another 
example of COlnmon polypharmacy seen in the literature is the use of medications to deal with side 
effects of other medications (Branford, 1996). For example, anti-Parkinson drugs are prescribed to 
help the Parkinson-like side effects that result from the use ofneuroleptics; this, however, is often 
discouraged because of its propensity to result in tardive dyskinesia. 
Drug review programs. 
Malpractice lawsuits began to develop in the United States due to the adverse side effects of 
psychotropic medication (i.e., development of tardive dyskinesia) and the inappropriate use of 
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medication. Sonle well known cases are Clites v. State of Iowa (1982); Faigenbaum v. Oakland 
Medical Center (1986); Hedin v. U.SA (1985); Wyatt v. Stickney (1972); Garrity v. Gallen (1981); 
Wuori v. Zitnay (1978); and, Welsh v. Likings, (1976) (as cited in Rinck, Guidry & Calkins, 1989). 
These court cases collectively resulted in an increased responsibility to develop better standards for 
those caring for individuals with ID; hence, drug review programs were developed and implemented 
in numerous state facilities (Poindexter, 1989). These programs provided much insight into the 
prescribing practices of the medical community in relation to individuals with ID. 
F or example, a study by Branford (1996) looked at a drug review program in Leicestershire 
with participants from ward-type accommodations (47 010), hostels (19%), group homes (14%) and 
private homes (21 0/0). In this study, antipsychotics were among the most prescribed (thioridazine, 
chlorpromazine, zuc1openthixol and haloperidol), with antiepileptics, antidepressants, anxiolytics 
and hypnotics also being prescribed, but less frequently. 
Briggs (1989) examined the long tenn effectiveness of an interdisciplinary drug review team 
in a residential setting for 697 individuals where monthly reviews were conducted and behavioural 
programs were implemented for challenging behaviour. Briggs (1989) found that psychotropic drug 
use remained at the low rate of 200/0, a dose reduction for 91 % of participants. The most often used 
medications were Haldol and Mellaril. 
Rinck et aI, (1989), in their study, looked at reVIewIng the States' practices usmg 
psychotropic medication. The methodology of this study included an analysis of important variables 
such as the dose levels of each drug; rules regarding polypharmacy; the use of anti-Parkinson drugs 
that could lead to the development of tardive dyskinesia; drug interruption times (i.e. holidays) to 
evaluate the effects of the absence of medication; and, the use of a minimum effective dosage. 
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Results of this study show that there are more regulations for institutionalized settings than 
community-based settings (Rinck et aI., 1989). 
Research shows that an outcome of the implementation of drug review programs is the 
developed guidelines regarding prescribing practices when delivering nledications to individuals 
with developmental disabilities; one such guideline being that psychotropic medication should not 
be used excessively, and should not be used as punishment or for staff convenience (Rinck et aI., 
1989). Psychotropic nledication should be used as part of a multidisciplinary care approach within 
the context of a diagnostic and functional assessment. Specific behaviours should be tracked, side 
effects should be monitored and regular and systemic reviews should be implemented. Moreover, 
the lowest effective dose should be implemented first, with frequent drug and dose changes avoided. 
In regards to polypharmacy, the medication regime should be as simple as possible, and long term 
PRN usages should be avoided (Bisconer et aI., 1996). 
Lepler et aI, (1993) conducted one of the first studies evaluating a psychotropic drug review 
process for individuals residing in a community placement. They found that utilizing an 
interdisciplinary team and a drug review program decreased psychotropic medication to a low rate 
of 17%, a reduction for 75% of participants. In this study, they also recommended using least 
intrusive measures first. Other studies found similar results in that these types of interdisciplinary 
teams and reviews are effective in reducing psychotropic medication use in institutionalized settings 
and in the community (Findhold & Emmett, 1990; Wressell et aI., 1990). 
In the 1980s, Michel and Kolakowska (see James, 1983) published guidelines regarding 
medication usage in response to concerns raised about the use of psychotropic medication in 
institutional settings. They recommended that polyphamlacy be completely avoided, that long-
acting drugs delivered on a frequent basis be avoided and that medication be reduced and or 
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discontinued if there was no evidence that it was indeed helping the patient (James, 1983). Thirty 
years later we are still facing these same issues when dealing with individuals with ID who exhibit 
challenging behavior in the community. 
A study by Emerson et aI, (2000) In a reVIew of treatment procedures found that 
behavioural programming was used for 15% of individuals with challenging behaviour; sedation 
was used for 35%, physical restraint was used for 440/0 and seclusion was used for 200/0. Also, 
Robertson et aI, (2005) found that reactive Inanagement strategies were most often used In 
congregate settings. Following this, they found that physical intervention was most common. 
Recently in Canada, Tools for the Primary Care of People with Developmental Disabilities 
(Developmental Disability Primary Care Initiative, 2011) have been published, with a specific 
section regarding psychotropic medication use recommending the following: (a) antipsychotic drugs 
no longer be used as routine treatment for challenging behaviours since other interventions are 
effective in treating behaviours; (b) attention be given to individuals on multiple medications due to 
potential adverse reactions; (c) there be a review of psychotropics every three months; (d) 
addressing behavioural crises and using nledication as needed is permitted but this must be reviewed 
and explained to the caregivers; (e) medication doses should be started low and increased 
gradually; (f) individuals be monitored for side effects; and (g) a record be maintained of all 
prescriptions. There are also guidelines specific to the use of Pro Re Nata (PRNs), for example: (a) 
integrate PRN s into the overall treatment plan for the individual; (b) set a review time at the time of 
the PRN prescription and note why it was prescribed; (c) discontinue PRNs that have not been used 
for six months or longer; and (d) avoid prescribing more than one mediation for anyone symptom. 
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The few guidelines reported above have COlne from various countries during different time 
frames but they all allude to the same standard of care essential in ensuring the safety of the 
individual with ID. 
Medication Use in Institution and Community Settings 
Research has been conducted on the use of psychotropic medication in institutionalized 
environments since the 1960s. Studies conducted on deinstitutionalization are published fronl 
countries such as England, Canada, United States, Scotland, and Norway. It is reported that the 
rates of antipsychotic medication use in the institutions are as high as 40.2% (Clarke et at, 1990). 
Other reports show med}cation (antiepileptic and psychotropic) use as high as 50% (Harder, 
Kalachnik, Jensen & Felts, 1987). Research conducted in more recent years show similar results. 
For example, Robertson and colleagues (2000) showed that psychotropic medication rates in an 
institution ranged between 250/0 - 50%. 
Some studies suggest that even though psychotropic medication use in the institution is 
reported to be very high, there is inconsistency in results when it comes to comparing residential 
and community-based settings. Some authors have indeed found that the institution environment is 
associated with higher rates of medication when compared to the community. For example, in the 
Robertson et aI, (2000) study, psychotropic medication use in the community was reported to be 
270/0 in community-based housing, whereas psychotropic medication use in the institution was 
reported at 560/0. Those residing within private homes had a much lower rate of medication use at 
1 7%. Branford (1997) reported statistics in that about 30 - 50% of individuals in institutions 
received psychotropic nledication in comparison to 20 - 30% of individuals in the community and 
10% of individuals living in private family homes. Other studies showed that rates in the 
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community and the institution remained the same (Emerson & Hatton, 1996; Nottestad & Linaker, 
1999). 
Currently, the literature presents a divided view regarding the use of psychotropic 
medications in the institution versus a community-based setting. Many studies have looked at 
psychotropic medication use in only an institutional environment (Briggs, 1989; Fischbacker, 1987; 
Poindexter, 1989; Rinck, Guidry & Calkins., 1989; Stone, Alvarez, Ellman, Home & White, 1989) 
and many studies have also only looked at psychotropic drug use in a community-based setting 
(Am an et aI., 1985; Bisconer et aI., 1996; Burd et aI., 1991; Gowdey et aI., 1987; Martin & 
Agran, 1985; Zaharia & Struxness, 1991). These studies were conducted in different countries 
during different time periods and used a diverse array of methodologies. 
Medication Use in the Institution. 
Stone et aI, (1989) conducted a study of 6,450 individuals institutionalized with an ID. They 
found that medication use was divided into 6 classes (antipsychotics, antidepressants, anxiolytics, 
sedative / hypnotics, stimulants and other). They reported that in an institution located in California, 
35.60/0 (range =13.7% - 63.60/0) of their entire population of individuals with ID were taking 
psychotropic medications. The mean antipsychotic drug use was 26.8% (range = 11.00/0 ,. 59.60/0) 
among participants residing in the institution. In comparison to other studies conducted, this was a 
wide range for medication use, as some reports were quite low in this regard. The authors report 
that these low rates may be a result of drug programs. Silva (1979) reported on a sample of 260 
participants that 65.80/0 were prescribed at least one medication. The class of medications 
prescribed nlost frequently were nlajor tranquilizers (Phenothiazines: i.e., mellaril or thiorisazine 
and haldol). The second most used medication class were anticonvulsants (i.e., dilantin, nlysoline, 
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tirdione and zarontin). Individuals were also given phenobarbital but this was classified under a 
sedative/hypnotic which was the third most prescribed class. Minor tranquilizers (i.e., 
hydroxyzines, benzodiazepines and carbamates) were aIllong the least prescribed. The authors 
included a fourth class of miscellaneous medications that reflected drugs such as antibacterial, 
analgesics, antibiotics, diuretics, hormones, laxatives, vaginals and vitamins, to name but a few. 
21 
Fischbacher (1987) reported on a residential setting for individuals with 'mental retardation' 
in Scotland and using a classification system similar to Stone et aI, (1989). They reported on 
anticonvulsants, antipsychotics, antiparkinson drugs, emergency sedation, tranquilizers, 
antidepressants, replacement therapy, laxatives and contraceptives. A high percentage of their 
population exhibited seizures (182 out of a sample of 509) and as such, anticonvulsants were among 
the highest class of medications prescribed, including carbamazepine, phenytoin, sodium valproate, 
primidone and phenobarbitone. One third of the residents were taking antipsychotics (thioridazine 
and chlorpromazine) and two thirds were using haloperidol, droperidol and even lithium in a few 
cases. The authors reported that antidepressants were used infrequently because of the difficulty in 
recognizing depression in the ID population. 
Polypharmacy in the institution. 
Robertson et aI, (2000) reported that in the residential setting, participants are n10re likely to 
receive antipsychotics and antidepressants than individuals in community or dispersed housing. In 
Branford (1997), two different time frames were compared and the results found were different to 
those in the Robertson et aI, (2000) in that there was an increase in participants receiving 
antipsychotic and antiepileptic drugs. Branford (1997) noted that there were high rates of the 
prevalence of antipsychotics used in combinations with other psychotropic medication classes likely 
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attributed to physicians adding risperidone to the medication regime without stopping other 
medications. In Molyneux et aI, (1998), nearly half the individuals were found to be receiving 
neuroleptics and antidepressants; this combination of medications being consistent with findings 
from Robertson et aI, (2000). However, an American study by Briggs (1989) of a residential facility 
illustrated that the most consistent polypharmacy combination were antipsychotics and anxiolytics, 
and then, antipsychotics and lithium. An Australian study by McGillivray & McCabe (2005) with 
data from 1993 and 2000 revealed that in the year 2000, individuals were administered a Inean of 
1.7 drugs in the institution and 1.5 in the cOlnmunity, with those residing in the institution being 
more likely to receive three or more different drugs than those in the community. Alternatively, in 
the 1993 sample, polypharmacy was equal among community and institution-type settings. The 
percentage of individuals medicated across both time frames (recurrent sample) was more likely to 
receive more medications than those medicated across only one time frame. 
Polypharmacy is affected by variables such as how long the individual was receiving 
medication and the nature of their challenging behaviours, as well as duration of time of symptoms 
(McGillivray & McCabe, 2005). The region in which the study was conducted may also have 
implications on polypharmacy; for example, in the United States, 21 states had regulations 
regarding the practice of polypharmacy for individuals in institutions, whereas there were no such 
regulations for individuals in the community (Rinck et aI., 1989); hence this may have affected 
prescribing practices. Different studies showed different prevalence rates of different combinations 
of drug classes used but there are no clear and consistent findings. Polypharmacy is a necessary 
variable when studying medication use in individuals with ID because, as the research indicates, 
even in the most recent studies, it is still a concern. 
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Medication use in the community. 
Studies have also looked at medication use in a community-based setting. Most studies were 
conducted using an adult population, with the exception of Aman et aI, (1985), who included 
children in their sample. The majority of studies also used a questionnaire to gather information 
regarding medication. Common variables reported in studies conducted in a cOlnmunity-based 
setting were similar to those studies conducted in institutional settings, such as information on 
challenging behaviour, presence of a psychiatric diagnosis and / or the prevalence of polypharmacy. 
Martin and Agran (1985) conducted a study including different variables than those 
previously mentioned. T.hey looked at individuals in a community setting (apartments, single family 
home, psychiatric hospitals that provide short term service and or a nursing home). They collected 
data regarding the history of institutionalization, a variable not mentioned in many studies. Their 
results show that forty-nine percent of participants did not have a history of institutionalization. 
Alternatively, those with a history of institutionalization (700/0 of the 49%) were taking psychotropic 
and/or anticonvulsant n1edication at the time of the file review. By comparison, only 27% of those 
without a history of institutionalization used psychotropic medication. An interesting finding is that 
640/0 of individuals without a history of institutionalization had received anticonvulsants in 
comparison to 41 % who had been institutionalized. They also found that psychotropic and 
anticonvulsant medication use increased as individuals were living and/or working in restrictive 
settings. This study provides some evidence that psychotropic medication may be just as high in the 
community as in residential settings, as almost half the individuals in their sample were receiving 
medication. A limitation of this study is that they did not include infonnation on polypharmacy. 
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Published studies tend to differ in their classification of psychotropic medication. For 
example, Burd et aI, (1991) included classes such as porpanalol, antihypertensives, lithium 
carbonate and hydroxyxine in addition to the classes mentioned in other studies (neuroleptics, 
antidepressants, antianxiety and anticonvulsants). This study also differed from previous ones in 
that they found anticonvulsant medications to be the most used drug group, higher than neuroleptics. 
However, Burd et aI, (1991) found that psychoactive medication was only used by 370/0 of their 
sanlple, which was much lower than what Martin and Agran (1985) reported. Their participants 
were different in that Burd et aI, (1991) looked at individuals in group home settings who were 
exposed to more restrictive work and living conditions than were presented in Martin and Agran 
(1985). However, both authors agree that these statistics are consistent with medication levels in an 
institutional environment. 
- An Ontario based study conducted by Gowdey et aI, (1987) surveyed 1,389 residents 
looking at the names, doses and frequency of administration. Their results revealed that 40% of their 
sample received psychoactive drugs (230/0 anticonvulsants, 14% neuroleptics, 5% sedative / 
hypnotics, 3% antidepressants, 30/0 antiparkinsons and 1 % antimanics). However, they did suggest 
that the frequency of prescribing anticonvulsant and neuroleptic medication was much less for 
community-based settings that those residing in institutions (Gowdey et aI., 1987). Gowdey et aI. 
(1987) has comparable rates of anticonvulsant use of 22.50/0 to that of Zaharia and Struxness (1991) 
who found anticonvulsant use at 21.8% in their sample. 
Bisconer et aI. (1996) reviewed psychotropic medication in a sample of 97 participants. 
Case managers, who cOlnpleted a two-hour training, were assigned to give surveys to the 
participants. Drug classes used were consistent with previously cited studies. This study shows that 
88.7% of participants were taking neuroleptics (in order of prescription, thiordazine [53 
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prescriptions], haloperidol, chlorpromazine, trifluoperazine, perphenazine, mesoridazine and 
thiothixene). The duration of time individuals were taking neuroleptics was between 2 months to 
28.3 years. After neuroleptic use, there were 13 individuals taking antiparkinson medications for 
durations ranging from two months to thirteen (13.20/0) years. Moreover, one individual was taking 
Phenobarbital (anxiolytic / hypnotic) continuously for fourteen years. 
Studies conducted in the community-based setting indicated that medication use was still, in 
some cases, as high as in an institutional setting (Branford 1997). More studies are needed on 
comparing a comn1unity-based versus an institutional setting with participants transitioning from an 
institutional setting to a community-based setting. As Martin and Agran (1985) found, the history 
of the participant has an, impact on the n1edication they receive. Therefore, an important variable in 
reviewing studies conducted is detern1ining / looking at individuals with a history of 
institutionalization. 
Polypharmacy in the community. 
In a community-based study of 1,389 participants in Canada, Gowdey et aI, (1987) found 
that one half of the residents received two or more psychoactive drugs a day. Also, 56% of 
individuals taking anticonvulsants were on two or more a day. Zaharia and Stuxness (1991) also 
showed in their community-based sample in Colorado that multiple psychotropic drugs were 
delivered within a class. Combinations reported in order of most utilized are 1) anti -convulsants + 
anti-psychotics; 2) anti-parkinsonian + anti-psychotic; 3) lithium + anti-psychotics; 4) anti-anxiety + 
anti-psychotic; 5) lithium + anti-convulsant; 6) anti-depressant + anti-convulsant; 7) anti-depressant 
+ anti-anxiety; 8) anti-depressant + anti-parkinsonian; 9) lithium + anti-parkinsonian; and, 10) 
lithium + anti-anxiety. In another study conducted in a group home setting, Burd et aI., (1991) did 
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not report on the specific combinations but reported that out of 809 participants, 370/0 were taking 
one or more medications; 120/0 were receiving two or more; and two residents were taking six 
different psychoactive medications while 49 individuals were reported to be taking medication from 
two different drug classes. 
A Norwegian study by Holden and Gitlesen (2004) reported lower rates of polypharmacy 
than the North American studies. In a sample of 300 adults, only 27 (9.20/0) were reported to be 
taking two medications and seven (2.4%) were reported to be taking three; the total prescriptions 
written per participant being 1.37. 
Comparisons of Medication Use in Institution and Community Settings. 
There are numerpus studies con1paring individuals living in the community with individuals 
living in an institution in order to better evaluate psychotropic medication use. These studies have 
been published in a wide array of countries (Branford, 1997; Harper & Wadsworth, 1993 ; Harper, 
Wadsworth & Michael, 1989; McGillivray & McCabe, 2005; Molyneux et aI., 1998; Thinn, Clarke 
& Corbett, 1990; Nottestad & Linaker, 1999; and Robertson et aI., 2005). 
An English study published by Branford (1997) served as a follow-up study to an initial 
study conducted in 1990. In 1990 they surveyed 486 residents, 93% of whom lived in ward-type 
settings. Of these 486 participants, 44% were taking antipsychotic drugs, 44% were taking 
antiepileptics, 6% taking antidepressants, 13% taking anticholinergics, 3% taking anxiolytics and 
5% taking hypnotics. In 1996, the authors were able to locate 394 of the original 486 participants. 
Of the 394 participants, 32% lived in ward type accommodations, 240/0 in health-care group homes, 
130/0 in social-care homes and 31 % in private homes. Results showed that in the 1996 sample, the 
prescription of antidepressants increased significantly. There was also an increase in the 
polypharmacy of antipsychotic and anti epileptic drugs. Branford (1997) suggested that 
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psychotropic medication in the conlmunity may be as equally high as psychotropic medication in 
the institution because community settings are less likely to tolerate behaviours that were acceptable 
in institutionalized settings. Even though there was little change in the overall frequency of 
prescribing of medicines, the type of medicine prescribed for each patient was different in 1990 
versus 1996. A limitation of this study is that during 1990 to 1996, Leicestershire residence in 
England went through changes as a result of the de institutionalization era (i .e. the closing down of 
residential-type accommodations and drug review progranls). The results of this study should 
therefore be understood within this context and should not necessarily be generalized to studies 
conducted in countries that were not going through the same type of reformation. 
Another English.study conducted by Robertson et aI, (2005) cOlnpared the nature and 
prevalence of procedures used to treat challenging behaviour. Within the context of this study was 
the us.e of psychotropic medication as a treatment choice. This study was part two of a study 
conducted in 2002. Data was collected at two points in time, ten months apart, in two types of 
settings. The first being a congregate setting where the majority of the participants had challenging 
behavior and the second being a non-congregate setting where the minority of residents displayed 
challenging behaviour. Robertson et aI, (2005) used a longitudinal matched groups design on a 
sample of 50 participants (25 participants from a congregate and 25 from a non-congregate setting). 
A research analyst visited each client for 10 hours at time one (Tl) and six hours at time two (T2). 
At T2, more participants in the congregate setting were reported to receive more antipsychotic 
medication (800/0) in comparison to non-congregate settings (500/0), but not at Tl. Typical 
antipsychotics were lnost often prescribed in both congregate (64%) and non-congregate (440/0) 
settings at both TI and T2. The authors suggested that prescriptions did increase due to the recent 
release of risperidone. Limitations of this study include the presentation of only correlational data 
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between methods of treatment and setting. Also, the duration of time between Tl and T2 was 
relatively short (i.e. 10 months). Participants in the congregate settings were reported to have more 
challenging behaviours than the pmiicipants in the non-congregate settings. This might explain 
higher rates of medication use. 
Hemming, Lavender, and Pill (1981) and Thinn et aI, (1990) reported on a study conducted 
by Hemming (1984) where 51 adults with 'mental retardation' transferred from a large institutional 
setting into a small unit setting, with 50 controls remaining in the institution. Prescriptions were 
studied at 5 different times (before transfer, intervals of four months, nine months, one year and two 
years after transfer). Results from Hemming's 1981 and 1984 (see Thinn et aI., 1990) studies show 
a significant increase in pntipsychotic medication prescriptions for transferred residents 4 months 
after transfer and a significant increase in the use of sedatives 9 months and one year after transfer. 
This study brings up the important analysis of the effects of transitions on individuals with ID and 
medications necessary to help ease 'anxiety' during this tinle. 
Thinn et aI, (1990) conducted a study in England comparing psychotropic drug use before 
and after discharge from hospital to community. They examined case notes for 81 participants with 
'mental retardation' (moderate to severe retardation, 36 of whom had a seizure disorder) who had 
moved from two hospitals into the community between 1983 -1987. All participants had been 
residents of the community for at least six months. Data was collected (retrospectively) by 
recording all drugs prescribed to a participant (a) two years before discharge; (b) on the date of their 
discharge; and (c) at the time of a survey. This study only dealt with psychotropic and antiepileptic 
medication. Results indicated that the average time spent by participants in the comillunity was 
twenty five months. As for participants psychotropic medication use 37.5% were receiving 
antipsychotics two years before discharge, 390/0 at discharge and 39% after living in the community; 
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for antiepileptics, 30% two years before discharge, 33% at discharge and 33% at follow-up. 
According to this study, medication use did not change significantly when individuals moved from a 
residential setting into a community-based setting. Thinn et aI, (1990) suggested using a longer 
period of observation time in future studies. 
Harper et al. (1989) conducted a similar study with 87 participants. Most participants had 
moderate mental retardation whereas other studies published included participants with a wider 
cognitive range. Participants that were analyzed lived in 6 congregate settings and 18 group care 
environments. The only distinguishing factor reported between environments is that congregate 
environments included 15 or more persons living per facility and the group care environments 
included 4 to 15 per facility. Research was gathered by an interviewer collecting information (on 
problem behaviours and medication use) during a forty minute session with the participant, their file 
and a·staffmember who knew the individual for up to four n10nths. Psychotropic medication or 
anti epileptic medications were given to 49% of the population. Of those receiving medications, 
600/0 received them continuously for five years or longer. Medications used in order of highest to 
lowest were phenothiazines, butyrophenones, antidepressants, lithium carbonate and amitriptlyline 
hydrochloride. The authors noted that individuals with lllore severe problem behaviours were more 
likely to be in congregate settings. This was a limitation of lllany studies conducted before 
deinstitutionalized has ceased. Studies may have shown skewed results because those with the lllost 
challenging behaviours (and therefore, likely on higher rates of medications) were either the last to 
leave or in some cases, placed back into an institutional placement after a community placementhad 
failed. This study also concluded that there were higher rates of medication use among those older 
in age, as well as, those who had lived in an institution for a long period of time. Future research 
should focus on lllore controlled studies to identify issues beyond size and location. Nevertheless, 
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this study highlighted some relevant factors regarding psychotropic medication use such as (a) 
length of time in the institution; (b) age of participants; (c) severity of problem behaviours; (d) staff 
tolerance; (e) staff client ratio; and (f) philosophy of the attending physician. 
Investigating the role of the physician has been shown to be important in other studies. 
Molyneux et aI, (1999) conducted a study in a community setting in Norway looking at factors that 
predicted psychotropic medication use. One in five adults was prescribed a neuroleptic medication 
(chlorpromazine, haloperidol, zuclopenthixol & trifuloperazine) and this was predicted with 85% 
accuracy if the participant had challenging behaviour, a mental health problem, resettled from a 
long-stay hospital and was under the review by a consulting psychiatrist. One in ten participants 
was also prescribed anti;-depressants (amitriptyline, fluoxetine, paroxetine) and anxiolytics / 
hypnotics (diazepam, chloral hydrate, nitrazepam & telnazepam). This study extended the literature 
because it was one of few studies looking at the variable of a General Practitioner (GP) who 
provided care to individuals who had an ID in pritnary health care settings. This study also noted 
that the percentage of adults receiving anti-depressants was higher than in other community-based 
samples. Holden and Gitlesen (2004) reported in their study of prescribing practices in adults with 
'mental retardation' that at times there were both a GP and a psychiatrist involved. Both of whom 
sometimes prescribed different medications. Psychiatrists tended to prescribe second generation 
neuroleptics and GPs tended to prescribe more antidepressants. 
McGillivray and McCabe (2005) exatnined the associations between changes in medication 
use across a seven year time frame and the type of residential facility. All participants were 
receiving medication for behavioural restraint. The study was conducted as a comparison of the 
years 1993 (762 participants) to 2000 (873 participants) and included children and adults as 
participants. Participants that appeared in both samples (recurrent sample, and non recurrent 
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samples) were 318. Data was collected by looking at all reported cases of chemical restraint 
received by the Intellectual Disability Review Panel (IDRP). Other information gathered included 
gender, age, type of residential facility, nunlber and type of medications (clonazepam was classified 
as a sedative and lithium was included under anticonvulsants), as well as, PRN use. The percentage 
of individuals reported to be using 'chemical restraints' in the 2000 sample was similar across the 
community (21.1 %) and institution (22.5%). However, in the 1993 sample, those reported to be 
using 'chemical restraints' was higher in the institution (29.3%) versus the community sample 
(17%). In 2000, polypharmacy was higher in the institution sample but when looking at the total 
medication use the mean number of drugs delivered in 1993 was less than in the 2000 sample. A 
number of factors couldl1ave accounted for the results seen in the year 2000. For example, 
individuals may have been taking tnedications since 1993 and therefore taking more medications by 
the year 2000. The most frequent drug type to be administered was antipsychotics in the 2000 
(institution) and 1993 (institution and community) samples. Psychostimulants were also more likely 
to be given to participants in respite care. In the 2000 sample they were more likely to be given 
antianxiety/sedative and anticonvulsant/mood stabilizer drugs in comparison to the sample in 1993. 
Looking more specifically at the recurrent sample, 64.1 % of this sample had lived in the institution. 
The recurrent sample also had higher rates of being administered more than one drug (35.30/0) 
compared to 25.8% in the limited sample. In summary, there were no differences in the 2000 
sample regarding the proportion of individuals receiving drugs. However, individuals in the 
institution did receive a greater number of medications concurrently than those in the community 
sample. In 1993, drug use was greater among those living in the institution than alTIong those in the 
community. Yet, a limitation of this study was that participants in the community setting may have 
been individuals who were easily tTIanaged in a community placement and therefore placed there for 
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that reason. Alternatively, those in an institutional environment may have had higher rates of 
challenging behaviours and therefore, more likely taking medication. As such, future research 
should be conducted where this selection bias does not exist. 
An English study by Clarke et aI, (1990) compared the use of antiepileptic medications 
(during 1985 -1987) in three residential settings. This study is important as it specifically reports 
that antiepileptic medication use is reported to be as equally high (between 20 - 45%) as 
psychotropic drug use. Information was gathered from the adult training center (these adults 
typically lived in the community, respite or family homes) and the mental handicap hospital. 
Specially trained informants collected information from participants through a questionnaire 
interview. No information was gathered about the drug doses and names. However, a record of 
whether the drug was a psychotropic or epileptic was obtained. Antiepileptic and psychotropic 
medications were shown to be higher in the institutions than in community placements. These 
findings are contrary to those of Thinn et aI, (1990). 
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In summary, most studies conducted on medication use in a community versus a residential 
setting were carried out during the deinstitutionalization era. Studies by Thinn et aI, (1990), 
Nottestad and Linaker (2003) and McGillivray & McCabe (2005) included an analysis of settings 
across three points in time with the same participants. Most other studies did not include a 
longitudinal analysis of psychotropic medication with a sample of participants that had relocated 
from the institution to a cOlnmunity setting. Many studies compared a sample of participants in an 
institution environment to a smnple of participants in a community setting. There is a selection bias 
that exists with this type of method, as it is likely that a sample of those in institutions were residing 
in the institution due to their challenging behaviours and or multiple/psychiatric diagnoses. Both of 
which, have been shown to be positively correlated with higher rates of medication usage. 
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Future research should focus on studying psychotropic medication use within the context of 
post deinstitutionalization (relocation), where participants who now live in community-based 
settings will be compared to themselves when they use to reside in the institution. 
Summary 
The literature is inconsistent regarding the type of residence that has higher rates of 
medication use (i.e. the institution or the community-based setting). But, the literature is clear 
regarding low rates of medication use in private homes in comparison to community-based settings 
and institutions. Many studies suggest that psychotropic tnedication is the most often prescribed 
medication in both community and institution-type settings. Nonetheless, there are studies that 
show anticonvulsant and antiepileptic drugs are highly prescribed as well (Aman, Carolyn, Field & 
Bridgman, 1985). There are many important variables when studying medication use such as, the 
size of the setting and/or the restrictive nature of the setting, severity of the disability, challenging 
behaviours and prescribing practices (Martin & Agran, 1985). 
Given all of these factors, it is necessary to continue to conduct research that allows us to 
systematically test these hypotheses. Also, the location of the study conducted may have 
in1plications on the findings. For example, studies conducted in the United States and England often 
tend to have drug review programs in operation that mayor may not affect the results of the study. 
Even within the United States, different states have different regulations that affect their prescribing 
practices (Bisconer, Sine & Zhang, 1996). Research has been conducted in countries such as 
Norway, Scotland, Australia, United States, England and Canada, though very few studies have 
been conducted in Canada regarding psychotropic medication (Gowdey et aI., 1987; Sokolowski, 
2011). As such, more future research should be focused on Canada and its use of psychotropic 
medication. 
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A major limitation of the methodologies of the studies reviewed is the comparison of 
different individuals at one point in time who resided in two different settings (i.e. the institution 
and or the conlmunity-based setting), as opposed to, comparing the same individuals who resided in 
the institution to their relocation in the community (longitudinal design). When comparing the 
former, it is noted that individuals residing in the institution were likely there because they exhibited 
higher rates of challenging behaviour than those who had already transitioned (typically used as the 
comparison group). This dynamic likely skewed the results of studies. There is a lack of studies 
using the latter design. More studies need to be conducted with this type of methodology. Also, the 
time of data collection post relocation should be longer than six months as suggested by Thinn et aI, 
(1990). 
The purpose of this study is to extend the literature by conducting research on individuals 
with ID who have relocated from facilities to community settings in Canada. There have been no 
studies published in Canada on psychotropic medication use of individuals post the 
deinstitutionalization era. Therefore, this study aims to provide useful information that allows us to 
compare prescribing practices in Canada with those of other countries, as well as, to better the 
quality of lives of individuals with ID residing in Canada. 
Future research should indeed definitely include lllore studies conducted in Canada, as very 
few of them have been done (Gowdey et aI., 1987; Sokolowski, 2011) within the context ofa 
Canadian deinstitutionalization setting. 
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Research Questions 
The purpose of this study is to describe the patterns of usage of psychotropic medication among 
a population of 120 individuals with ID who lived in an institution and now reside in a community-
based setting. Specifically, this study will address the following research questions. 
1. What is the prevalence of psychotropic medication use for people who transitioned from the 
facilities to the community? 
a. How tnany people took psychotropic drugs in the facilities and in the community? This 
question will provide an analysis of four groups: 
I. Individuals who took psychotropic medication in the facility and community; 
II. Individuals 'who took medication in the facility but not in the community; 
III. Individuals who took medication in the community but not in the facility and 
IV. Those who were not taking psychotropic medication at all. 
b. Do the people in these groups differ with respect to their: 
I. Age, tinle out of facility, 
II. Adaptive behaviour (SIB-R), 
III. Problenl behavior (BPI), and, 
IV. Mental Health (REISS)? 
2. What types of medications were used in the facilities and communities, and did this change? If so 
how? This question will more specifically look at. 
a. Class 
b. Specific medications 
c. Number of psychotropic medications 
d. COlnbinations of medications, and, 
PSYCHOTROPIC MEDICATION USE 
e. PRN medications 
3. Do the individuals taking psychotropic medications have: 
(a) Psychiatric diagnoses, and, 
(b) Access to mental health care? 
36 
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Method 
Research Design 
This study is a longitudinal study on psychotropic medication use in among individuals with 
ID who are part of the de institutionalization process. Data has been collected in two points in time 
(Tl = the last assessment in the facility and T2= the first assessment in the community). The data 
from this study was collected as part of a larger project: The Facilities Initiative project led by Dr. 
Rosemary Condillac and Dr. Dorothy Griffiths. 
Participants 
Participants were 120 adults ranging from 33 to 77 years of age with varying degrees of 
cognitive abilities recruited from the last three residential settings to close in Ontario. Letters of 
invitation were sent to a total of975 participants with aID, 120 of which are included in this study. 
Data -Collection 
Consent to contact forms were sent to the family members and community support agencies 
of 943 former residents of facilities in Ontario by the Ministry of Community and Social Services. 
Project coordinators contacted potential participants via telephone to provide additional information 
regarding this part of the study. Those interested in participating, were sent specific letters of 
information and consent forms for the individual and for a staff participant. Once consent was 
obtained, a visit was booked for the research assistants (RAs) to visit their place of residence to 
collect data. During the visit, the RA sought assent from the individual with ID. If individuals 
displayed any behaviours that the RA and direct-care staff interpreted as a request to terminate the 
interview or observations, the RA would cease the interview. One participant requested to terminate 
the interview after the InterRAI ID was completed, though that participant asked to have her data 
retained for use. 
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Measures to Describe Sample 
Scales of independent behaviour-revised. (SIB-R; Bruininks, Woodcock, Weatherman & 
Hill,1996). 
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The Scales of Independent Behavior-Revised (SIB-R) is a norm referenced assessment that assesses 
14 areas of adaptive functioning and 8 areas of problem behaviour. The 14 areas of adaptive 
functioning fall under the following five categories (1) motor skills; (2) social interaction; (3) 
communication skills; (4) personal living skills and; (5) community living skills. The SIB-R short 
form was delivered pre-assessment and took 15-20 minutes to deliver. The support score was used 
to calculate adaptive functioning, with a higher score meaning less help needed. For the purposes of 
this study, only the adaptive measures were computed and used in this study, as problem behaviour 
scores will be computed using a different measure. 
- Psychometric properties for the SIB-R show that mean split-halfreliabilities for adaptive 
behaviour ranged from 0.88-0.98. Test-retest reliability coefficients ranged from 0.96-0.97. 
Behaviour problems inventory. (BPI; Rojahn, 1984). 
The BPI is a 52 item rating scale instrulTIent for individuals with ID that assess problem 
behaviour. Items on the instrulTIent include self-injurious behaviour; stereotypic, aggressive and 
destructive behaviours. All items are rated on a five-point frequency scale and on a three-point 
severity scale. The reliability and validity of this n1easure has been investigated. Test-retest 
reliability was poor for the stereotypy subscale but ranged frOtTI 0.67 to 0.7 for the other subscales. 
Internal consistency was found over most subscales ranging from 0.6-0.8. Lower internal 
consistency was found on the SIB subscale (OA-OA8). Validity results indicate that the aggressive 
and destIuctive sub scale had an r value of 0.55. Self injurious and stereotypic subscales scored r= 
0.21 and r=0.32 respectively (Rojahn, Matson, Lott, Esbensen & Smalls, 2001). For the purpose of 
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this study, the frequency scores of all sub measures are added together to create a problem 
behaviour score. A high score means more problem behaviours. 
The interRAIID. (Martin, Hirdes, Fries & Smith, 2007). 
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The interRAI ID (Martin et aI, 2007) is a 391 item scale spanning 20 domains. These 
domains are personal information, health service inquiry, cognition, communication, hearing and 
vision, physical functioning, self care, physical health medications, skin conditions, oral and 
nutritional status, psychiatric diagnoses, mental state indicators, life events, behaviour, psychosocial 
wellbeing and social supports, education, vocation, recreation, prevention, intervention and home 
environment. For the purposes of this study the physical health medication section will be used. 
The interRAI ID was created espe'cially for persons with ID and has been used to aid in the planning 
process regarding deinstitutionalization. The interRAI ID has been shown to have good 
psychometric properties. The interRAI ID has been tested on 160 community-based residents, 
showing acceptable levels ofintemal consistency. Cronbach's alpha ranged from 0.74 to 0.93. 
Majority of items exceeded standard cut-offs for acceptable reliability (Hirdes et aI, (2008). 
REISS Screen for maladaptive behaviour. (Reiss, 1994). 
The REISS is a 36 item tool across eight subscales that screens for mental health problems 
and psychiatric disorders in individuals with ID who are 12 years or older. The eight subscales 
include autism, psychosis, paranoia, depression (behavioural), depression (physical), dependant 
personality disorder and avoidant. A rater reviewed the 36 symptoms under these eight subscales 
and rated them as either no problem, a problem or a major problem. The REISS was filled out by a 
parent, a teacher or professional who worked with the individual and took 20 minutes to complete. 
Psychometric properties have been established for the REISS, which has shown the 
instrument is valid in screening certain psychopathology. Cronbach's alpha coefficient was .91 for 
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the total score and varied between .57 and .86 for thel0 psychometric scales. Children and 
adolescents who had a dual diagnosis received total scores approximately amounting to 1 standard 
deviation higher than those who did not have a dual diagnosis (Reiss, Valenti-Rein, 1994). 
Training. 
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Research assistants (RAs) hired for this study and were masters students and trained 
clinician in the field ofID. Research assistants were trained by the primary investigator and had an 
additional three days of training during which thorough explanations of all of the Ineasures were 
taught. 
Procedure 
1. Potential participants and their direct-support staff were contacted after they had initially 
submitted a consent-for-contact form. The study was explained to them in simple 
language and they were asked if they were still interested in participating. No measures 
were delivered at this time. 
2. Agencies and/or families of interested participants were contacted for follow-up. During 
this conversation the risks and benefits of the study were discussed. If they were 
interested, consent forms and letters of invitation were sent to them. 
3. When consent was received, an appointment was scheduled, and a detailed infonnation 
package to help them to prepare for the visit was sent, including three measures for them 
to complete in advance, the BPI, the SIB-R, and the REISS. 
4. At the scheduled appointment, assent was sought from the participant with ID, if the 
substitute decision maker had provided consent. The RA collected the measures that had 
been completed by the direct-support staff. The RA answered any outstanding questions 
and ensured that all questions on the pre-visit measure were completed. 
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5. The RA completed the interRAI ID with assistance from the direct-support worker and 
the clinical file as necessary. 
6. Other measures were completed for the full study, including interviews, direct 
observations, and file reviews. 
7. After the visit, interRAI ID data was entered into a secure on-line database by the person 
who completed the interview. 
8. All other measures were entered into the main study data base by trained research 
assistants who also scored, coded, and double checked all data entered. 
9. A master file for this study was merged using SPS S from the two data sets, and Inerging 
variables were triple checked to ensure accuracy. 
10. A medication classification system from the National Institute of Mental Health (NIMH, 
2010) was used to classify all psychotropic medications into (a) first generation 
antipsychotics, (b) second generation antipsychotics, (c) antidepressants, (d) anti-anxiety, 
(e) mood stabilizers / anticonvulsants, (f) hypnotics and (g) stimulants. All medications 
within these classes were coded into SPS S using a numerical classification system. 
Medications were identified that were not found in the NIMH medication list. These 
medications were cross referenced with a Developmental Pediatrician and a Psychiatrist 
as to (a) Ifit was a psychotropic medication and (b) what class listed in the NIMH list 
should they belong to. 
11 . The medications entered into the interRAI ID were string variables that needed to be 
hand coded to facilitate analyses. All psychotropic medications from the final 
medication list were numbered, and these numbers were applied to all psychotropic 
medications that were listed on the interRAI ID by the student investigator. 
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12. A research assistant conducted inter rater reliability (lRR) ratings on 250/0 of the data 
coded and found 99% agreement. 
13. Classifications of medications into classes were completed using algorithms created in 
SPSS to ensure accuracy. 
14. All analyses and cross tabulation were conducted using SPSS 19. 
Analyses 
Research questions regarding psychotropic medication examined: 
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1. Class of medication with a table showing frequency of use for each class at T1 and T2. As 
well as a description of specific class changes for those who changed 
2. Specific drug ~se with a' table of frequency of each type of medication T1 and T2 as well 
as a description of specific changes for those who changed. 
3. Number of psychotropic medications, total, mean, and description of specific changes for 
those who changed. 
4. Combinations of medications (prevalence of different combinations), frequency of 
different combinations T1 and T2 as well as descriptions of specific changes for those who 
changed. 
5. PRN use, the number and types of PRN meds as well as the description of specific 
changes for those who changed. 
All statistical analyses were performed using SPSS software and a significance 
(alpha) level of 0.05 was chosen for all analyzes. 
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Results 
Characteristics of the Sample 
Participants in this study were a total of 120 adults with ID (68 males and 52 females) who 
used to reside in facilities across Ontario. All participants are now living in cOlnmunity placements 
across Ontario. Each participant's age was calculated using the first community visit assessment. 
The age range of the participants is frOlTI 33 years of age to 77 years of age, with a mean age of 54.8 
years (see Table I below for entire sample demographics). 
Table 1 
Demographics Describing the Entire Sample 
Gender 
Men 
Women 
Demographic 
SIBR Support Level 
Intermittent 
Limited 
Frequent 
Extensive 
Pervasive 
Frequency 
68 
52 
3 
8 
32 
41 
33 
Note. The SlBR support level data is missing for three pa11icipants. 
Percent 
56.70 
43.30 
2.50 
6.70 
26.70 
34.20 
27.50 
A sumlnary of adaptive functioning as measured by SIB-R support levels (Table 1) shows 
that 3 participants (2.500/0) required intermittent support (borderline deficits). Conversely, 41 
participants (34.20%) required an extensive level (severe deficits) of support and 33 participants 
(27.50%) required pervasive support (profound deficits). 
Challenging Behaviour and Mental Health 
Table 2 shows participants' BPI scores. The BPI instrument contains six subscales under 
three types of problem behaviours (SIB frequency and severity subscales, stereotypy frequency and 
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severity subscales, and aggressive / destructive frequency and severity subscales). All frequency 
scores are rated between 0-4 and all severity scores are rated between 0-3 (4= the most frequent, and 
3= the most severe). Each problem behaviour scale has a different number of items. For example, 
the SIB subscale is rated on items 1-15. The highest possible score on the SIB frequency subscale is 
60 and the highest possible score for severity subscale is 45. On the stereotyped subscale there are 
25 items and on the aggressive / destructive subscale there are 12 items. In an effort to provide 
comparable scores, the total score per subscale was divided by the number of items in that scale 
providing a mean score per item that can be compared across scales. 
Table 2 
BPI and REISS Scores/or Participants in the Entire Sample 
BPI subscales N Min Max M SD 
SIB frequency scores 116 .00 1.4 0.31 0.32 
SIB severity scores 114 .00 1.4 0.23 0.25 
Stereotyped frequency scores 115 .00 3.3 0.74 0.71 
Stereotyped severity scores 113 .00 2.2 0.46 0.46 
Aggressive / destructive frequency 
scores 115 .00 1.8 0.25 0.34 
Aggressive / destructive severity 
scores 115 .00 2.6 0.3 0.41 
REISS total score (26 item) 116 00 46 6.14 6.82 
Based on descriptive statistics shown in Table 2, the highest mean scores are associated with 
both the stereotypy frequency and severity scores. Alternatively, low means were found in the SIB 
severity and frequency subscales. 
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Though there were many individuals in the sample taking psychotropic medication, few 
scored at or above the clinically significant range (cut-scores) on the Reiss (see Figure 1). As this 
measurement was taken while treatment was in progress, it is possible that the lower scores on this 
instrument indicate a positive treatment outcome. 
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Figure 1. Percentage of participants scoring at or above REISS cut-scores. 
Patterns of Psychotropic Medication Use 
Participants in our sample were classified into four groups. Group one consisted of those 
who used psychotropic medication in the facility and in the community. Group two consisted of 
those who did not use psychotropic medication in either setting. Group three consisted of those who 
used psychotropic medication in the facility but not in the community. Group four consisted of 
those who used psychotropic medication in the community but not in the facility. These groups are 
shown in Table 3. The majority of the participants (82.50%) belonged to groups where there was no 
change (either they were taking n1edications in both settings or not taking medication in either 
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setting). Some participants (17.700/0) experienced a change in psychotropic nledication status in that 
4.200/0 (5) of participants took medication in the facility but not in the community, and 13.300/0 (16) 
of participants took psychotropic medication in the comlTIunity but not in the facility (as indicated in 
bold). In total there were 89 (74.2 %) participants using psychotropic medications in the facility and 
100 (83.30/0) participants using psychotropic medications in the community. Psychotropic 
medication use was significantly higher in the community (X2 McNemar= 4.26, dj=l,p = .03) than 
in the facility. 
Table 3 
Psychotropic Medication Usage Across Settings 
Community 
Psychotropic 
Psychotropic 
% en) 
70 (84) 
Facility 
No psychotropic 
% en) 
13.30 (16) 
No psychotropic 4.20 (5) 12.50 (15) 
Note. Bolded values indicate the groups whose medication usage changed after relocating from 
facility to the community. 
Cross tabulations of these data with the support levels from the interRAI ID are presented in 
Table 4. AlTIOng the 83 participants who took psychotropic medications in both settings, 28 (330/0) 
of them required extensive support. Among the individuals who belonged to the group where 
psychotropic medication was used in the facility but not the community, frequent, extensive and 
pervasive levels of support were equally required. Half of the individuals who took nledication in 
the community, but not in the facility required extensive levels of support. 
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Table 4 
Cross Tabulation of the SIBR and Psychotropic Medication Groups 
Setting of psychotropic medication usage 
SIBR level of Facility only Community only Both Neither 
support (n =4) (n = 16) (n = 83) (n = 14) 
%(n) % (n) % (n) % (n) 
Intermittent .0 (0) 6.25 (1) 1.2 (1) 7.1 (1) 
Limited .0 (0) 6.25 (1) 7.2 (6) 7.1 (1) 
Frequent 25.0 (1) 18.75 (3) 27.7 (23) 35.7 (5) 
Extensive 25.0 (1) 50.0 (8) 33.7 (28) 28.6 (4) 
Pervasive 50.0 (2) 18.75 (3) 30.1(25) 21.4 (3) 
Note. There are three missing SIBR scores and therefore the total n does not correspond to the total n in the 
psychotropic medication group chart. 
Table 5 shows t~e cross tabulations for the BPI (standardized scores) and the 4 medication 
groups. The highest level of BPI scores are associated with the stereotyped behaviour severity and 
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frequ~ncy subscales and the groups with no change in psychotropic tnedication use across setting -
meaning those who take the most nledications. The lowest BPI scores are associated with those 
participants who took psychotropic tnedications in the facility, but not in the community. 
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Table 5 
Comparison of BPI (standardized) Means Across Psychotropic Medication Groups 
BPI scale 
SIB frequency 
SIB Severity 
Stereotyped frequency 
Stereotyped severity 
Aggressive Idestructive 
frequency 
Aggressive Idestructive 
severity 
Setting of psychotropic medication usage 
Facility only Community Both 
(n = 4) only(n = 16) (n = 83) 
M(SD) M(SD) M(SD) 
0.25 (0.3) 0.31 (0.32) 0.34 (0.33) 
0.15 (0.14) 0.21 (0.2) 0.25 (0.3) 
0.63 (0.59) 0.48 (0.41) 0.79 (0.75) 
0.42 (0.37) 0.30 (0.23) 0.45 (0.48) 
0.10 (0.16) 0.31 (0.36) 0.25 (0.35) 
0.15 (0.20) 0.45 (0.68) 0.26 (0.37) 
Neither 
(n = 14) 
M(SD) 
0.22 (0.36) 
0.6 (0.21) 
0.75 (0.77) 
0.46 (0.55) 
0.23 (0.26) 
0.19(0.21) 
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Table 6 shows the cross ta\Julation of the REISS scores across the psychotropic medication 
groups. A possible mental health problem was indicated for 27 participants who received a REISS 
above cut score. Twenty-two of the 27 participants were associated with the above cut score and 
medications and both settings. This is an expected finding as a majority of individuals who showed 
a mental health indicator were also taking psychotropic medication across both settings. In addition, 
four individuals who have a REISS score above cut-off were also associated with medication use in 
the comillunity but not in the facility. 
Table 6 
Cross Tabulation of REISS Above Cut Scores and Psychotropic Medication Groups 
Above cut scores 
Facility only 
(n = 4) 
% (n) 
.0 (0) 
Setting of psychotropic nledication usage 
Community only Both 
(n = 16) (n = 82) 
% (n) % (n) 
25.0 (4) 26.80 (22) 
Neither 
(n = 14) 
% (n) 
7.10 (1) 
REISS total scores have also been cross tabulated with the four psychotropic medication 
groups (see Table 7). High mean scores are associated with those participants who took medication 
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in the community but not the facility. Second highest mean scores are found in the group that took 
medication in both settings. 
Table 7 
Cross tabulation 0/ REISS Total Scores and Psychotropic Medication Groups 
REISS total 
score 
Facility only 
(n = 4) 
M(SD) 
3.0 (2.9) 
Setting of psychotropic medication usage 
Comn1unity only Both 
(n = 16) (n = 82) 
M(SD) M(SD) 
9.3 (1.6) 6.1 (6.0) 
Neither 
(n = 14) 
M(SD) 
4.0 (3.3) 
Mean scores for the number of years participants were out of the facility is comparable 
across groups, as is the variability ,across participants in each group (see Table 8). The highest mean 
(3.7) was among those participants who did not need medication in either setting. The lowest mean 
(2.5) ~as among those who used medication in the facility, but not in the community. 
Table 8 
Cross Tabulation a/Time Out a/the Facility and Psychotropic Medication Groups 
Time out of 
facility 
Facility only 
(n = 5) 
M(SD) 
2.5 (0.7) 
Psychotropic Medication Use 
Setting of psychotropic medication usage 
Community only Both 
(n = 16) (n = 84) 
M(SD) M(SD) 
3.5 (1.6) 3.24 (1.3) 
Neither 
(n = 15) 
M(SD) 
3.7 (0.6) 
To further examine psychotropic medication use, Table 9 shows it simplified into three 
categories. Category (I) shows total number of psychotropic medication use, category (2) shows 
the daily number of psychotropic medication use, and category (3) shows PRN psychotropic number 
medication use. Under each category there are descriptive statistics for two samples: (a) the total 
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sample of 120 participants, and (b) the italicized sample of 120 participants with cases of those who 
did not take psychotropic medication selected out. As such, the sample size will vary under each 
category. 
Few differences were seen regarding the total number of psychotropic medication use among 
participants in the facility and the community (facility M=2.01 and community M=2.l). Even when 
cases of those who exclusively took psychotropic medications are computed (facility M= 2.6 and 
community M= 2.5), the lTIeanS are still very similar. Total number of nledication use in the facility 
had a slightly higher range of 0-7 psychotropic mediations use in comparison to the 0-6 in the 
comlTIunity. A paired samples t test shows no significant difference alTIong medication use between 
the facility and comlTIunity settings (t = -.87, df= 119,p = .389). 
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Table 9 
Psychotropic Medication Use/or the Total Sample in Last Facility and First Community 
Assessments 
N Min Max . M(SD) 
Category 1 
Total Number of Psychotropic 
Medication 
Facility 120 0 7 2.01 (1.7) 
Community 120 0 6 2.1 (1.5) 
Facility 89 I 7 2.7 (1.4) 
Community 100 I 6 2.5 (1.2) 
Category 2 
Daily Number of Psychotropic 
Medication 
Facility 120 0 5 1.53 (1.34) 
Community 120 0 6 l.89 (1.63) 
Facility - 85 5 2.15 (1.08) 
Community 79 6 2.87 (1.10) 
Category 3 
Number of Psychotropic PRN 
Medieation 
Facility 120 0 4 .48 (.78) 
Community 120 0 2 .20 (.46) 
Facility 41 4 1.4 (.67) 
Community 21 1 (.000) 
Daily psychotropic lnedication use was higher in the community (M=I.89) than in the 
facility (M=1.53). A paired samples t test showed that participants in the community had more 
frequent daily medications than in the facility (t = -3.30, df= 119,p = .001). 
PRN use was higher in the facility (M=.48) than in the community (M=.20) A paired t test 
was performed across groups to test for significance. Results showed that PRN use was significant 
among participants in the facility than participants in the community (t = 3.346, df= 119,p = .001). 
In summary, the total number of psychotropic medications used stayed consistent across settings, 
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yet participants in the facility had higher PRN usage than those in the community and participants in 
the community had a higher daily medication usage than those in the facility. 
Common PRNs. 
The most common PRN medications used across facility and community settings is shown 
in Table 10. Lorazepam was the most frequently used PRN, with 39 participants in the facility (32.5 
%) and 16 participants in the community (13.3 %). Diazepam was the second most commonly used 
PRN, with 6 participants in the facility and only one participant in the community. Some 
psychotropic medications, such as clonazepam, haloperiodol, oxazepam, prochlorperazine, 
temazepam and zopic1one, were used in the facility as a PRN, but were not used in the community. 
Table 10 
P RN Psychotropic Medication Use 
PRN Facility Community 
% (n) % (n) 
Chlorpromazine 2.5 (3) .8 (1) 
Clonazepalll 2.5 (3) 0 
Diazepam 4.9 (6) .8 (1) 
Haloperidol .8 (1) 0 
Lorazepam 32.5 (39) 13.3 (16) 
Olanzapine 0 1.6 (2) 
Oxazepam .8 (1) 0 
Prochlorperazine .8 (1) 0 
Quetiapine 0 2.5(3) 
Risperidone 0 .8 (1) 
Temazepam .8 (1) 0 
Zopiclone .8 (1) 0 
A closer look at the individual psychotropic medications used in the last facility and first 
community assessments showed that all five classes of psychotropic medications used in the NIMH 
list were prevalent among participants in the facility and the community (see tables 11 - 15). These 
include antianxiolytics, antipsychotics, antidepressants, mood stabilizers and anticonvulsants, and 
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ADHD medications. There were significant changes in the class of psychotropic medication used 
across settings. 
Antianxiolytics. 
There were more participants using antianxiety medications in the facility (52.50/0) than in 
the community (37.5%), X2 McNemar=6.57, clf-=1,p=.OI (see table 11). Among this class, more 
participants used lorazepam in the facility (40.80/0) than in the community (22.50/0). The least 
utilized psychotropic medication within the antianxiety class was zopiclone (1.7%) and temazepam 
(1.70%). Data shows that 32 participants were on antianxiety medications across both settings. 
There were 31 participants who took antianxiety medications in the facility, but did not take them in 
the community. Thirtee.n participants started antianxiety medications in the community. 
Table 11 
Antianxiety Medication Use at Last Facility and First Community Assessment 
Facility Community 
0/0 (n) % (n) Test Statistic 
X2 McNetTIar= 6.57, 
Antianxiety 52.5 (63) 37.5 (45) df=l, P .01 
Buspirone 10 (12) 3.3 (4) 
ClonazepatTI 5.0 (6) 9.2(11) 
Diazepam 8.3 (10) 2.5 (3) 
Lorazepam 40.8 (49) 22.5 (27) 
Oxazepam 6.7 (8) 5.0 (6) 
Temazepam 1. 7 (2) 2.3 (3) 
Zopiclone 1. 7 (2) .8 (1) 
Note: the first medication listed is the class (antianxiety), this number is a unique identifier showing how 
many participants used antianxiety medications n= 120. 
Antipsychotics. 
Participants in the community were significantly more likely to be taking antipsychotic 
medications (51.7%) than those in the facility, X2 McNemar=5.33, df= 1 andp = .02, see Table 12. 
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Within the class of antipsychotic medications, the most frequently prescribed medication was 
risperidone (23.3%), quetiapine (14.2%) and olanzapine at (1.70/0). No participants in the 
community sample were reported to take prochlorperzine. Haloperidol use decreased from 4.2% 
(facility) to 1.7% (community). Many participants were on antipsychotic medications in both 
settings (42) but 7 participants took antipsychotics in the facility but not in the community, while 20 
participants were taking antipsychotic medications in the community. 
Table 12 
Antipsychotic Medication Use at Last Facility and First Community Assessment 
Facility Community 
% (n) % (n) Test Statistic 
X2 McNemar=5.33, 
Antipsychotic 40.8 (49) 51.7(62) df= l,p <.021 
Chlorpromazine 3.3 (4) 4.2 (5) 
Haloperidol 4.2 (5) 1. 7 (2) 
Methotrimeprazine 5.8 (7) 5.0 (6) 
Olanzapine 5.8 (7) 11.7(14) 
Perphenazine .8 (1) 1. 7 (2) 
Pimozide 0(0) .8 (1) 
Prochlorperzine .8 (1) 0(0) 
Quetiapine 5.0 (6) 14.2 (17) 
Risperidone 20 (24) 23.3 (28) 
Zuclopenthixol .8 (1) 0(0) 
Note: the first medication listed is the class (antipsychotic), this number is a unique identifier showing how 
many participants used antipsychotics n= 120. 
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Table 13 
ADHD Medication Use at Last Facility and First Community Assessment 
ADHD medications 
Methy lphenidate 
Facility 
% (n) 
0(0) 
0(0) 
Community 
% (n) 
0.83 (1) 
.8 (1) 
Test Statistic 
X2 McNemar= 0.00, 
df= 1, P 1.00 
Note: the first medication listed is the class (ADHD), this number is a unique identifier showing how many 
participants used ADHD medications n=120. 
ADHD Medications. 
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No participants took ADHb medications in the facility, and only one participant was taking 
ADHD medications in the cOlnmunity (see Table 13). 
Antidepressants. 
There were significantly more participants using antidepressants in the community (32.5%) 
than in the facility (19.2%) X2 McNemar = 11.25, df= l,p < .001 (see table 14). The most 
frequently prescribed psychotropic medications in the community were citalopram (10%), trazodone 
(5%), fluoxetine (4.2%) and paroxetine (4.2%). 
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Table 14 
Antidepressant Medication Use at Last Facility and First Community Assessment 
Facility Community 
% (n) % (n) Test Statistic 
X2 McNemar=II.250, 
Antidepressant 19.2 (23) 32.5 (39) df= l,p <.000 
Citalopram 2.5 (3) 10 (12) 
Amitriptyline 1. 7 (2) .8 (1) 
Clomipramine 1. 7 (2) 3.3 (4) 
Doxepin .8 (1) .8 (1) 
Fluoxetine 4.2 (5) 4.2 (5) 
Fluvoxamine .8 (1) .8 (1) 
Imipramine 0(0) .8 (1) 
Paroxetine 3.3 (4) 4.2 (5) 
Sertraline 3.3 (4) 2.5 (3) 
Trazodone 1. 7 (2) 5.0 (6) 
Venlafaxine 0(0) 2.5 (3) 
Note: the first medication listed is the class (antidepressants), this number is a unique identifier showing how 
many participants used antidepressant medications n=120. 
Mood stabilizers / anticonvulsants. 
There were no statistically significant differences among participants' use of mood 
stabilizers and'anticonvulsants across settings (see Table 15). Mood stabilizer and anticonvulsant 
use in the facility was reported at 39.20/0 and 45.0% in the community sample. 
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Table 15 
Mood stabilizer / Anticonvulsant Medication Use at Last Facility and First Community Assessment 
Facility Community 
0/0 (n) 0/0 (n) Test Statistic 
Mood stabilizer / X2 McNemar = 1.57, 
anticonvulsant 39.2 (47) 45.0 (54) df=l, P =.210 
Carbamazepine 23.3 (28) 21.7 (26) 
ClobazatTI 5.0 (6) 5.8 (7) 
Divalproex 21.7 (26) 23.3 (28) 
Gabapentin .8 (1) .8 (1) 
Lamotrigine 3.3 (4) 5.8 (7) 
Lthiun1 carbonate 3.3 (4) 5.0 (6) 
Topiramate 2.5 (3) 5.8 (7) 
Note: the first medication listed is the class "mood stabilizer / anticonvulsant"; its number is a unique 
identifier showing how many participants used mood stabilizer / anticonvulsant medications n=120. 
A cross-tabulation of participants who were reported to have epilepsy and those who took 
mo04 stabilizers / anticonvulsants is found in Table 16. In the facility, among a total of 119 
participants, 47 were reported to be taking a mood stabilizer / anticonvulsant, while 33 participants 
(27.7%) had epilepsy and were also taking a mood stabilizer / anticonvulsant. In the community, 
among a total of 120 participants, 54 participants were reported to have been taking mood stabilizers 
and anticonvulsants, while 41 participants (34.1 0/0) had epilepsy and were also taking a mood 
stabilizer / anticonvulsant. A total of 39 participants were taking n100d stabilizers / anticonvulsants 
in both settings. There was some change across settings, in that eight participants had taken mood 
stabilizer / anticonvulsant medication in the facility but had not taken it in the community, and 15 
participants had taken mood stabilizer / anticonvulsant medication in the community but had not 
taken it in the facility. These are sOlTIewhat explained by the fact that 14 people had a change in 
epilepsy/seizure status in the community and 14 people no longer reported to have epilepsy / 
seizures in the facility. Our findings may also suggest that some participants were using mood 
stabilizers / anticonvulsants for other purposes than to treat epilepsy, as there were 14 participants in 
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the facility and 13 participants in the community who did not have a diagnosis of epilepsy but who 
still took a mood stabilizer / anticonvulsant. 
Table 16 
Epilepsy Diagnosis in the Last Facility and First Community Assessments 
Facility Community 
n=119 n=120 
Epilepsy No Epilepsy Epilepsy No Epilepsy 
Class % (n) %(n) % (n) % (n) 
Mood stabilizer / 27.7 (33) 11.8 (14) 34.1 (41) 10.8 (13) 
anticonvulsant 
Not taking a mood 24.5 (i9) 36 (43) 17.5 (21) 37.5(45) 
stabilizer / 
anticonvulsant 
Tables 17 and 18 show further descriptive statistics on the class of psychotropic medications, 
so as to provide a clear picture of the frequency of medications within classes an individual 
received. For exatnple, Table 17 shows that some participants were taking 5 mood stabilizers / 
anticonvulsants. The table also shows that there were participants taking up to 5 antianxiety 
medications. Looking at the same classes in the community, there were participants taking 3 mood 
stabilizers and 3 antianxiety medications. The least used class is ADHD medications. 
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Table 17 
Descriptive Statistics for Psychotropic Medication Classes in the Last Facility Assessment 
Facility 
Psychotropic class Min Max M (SD) 
Antipsychotic 0 4 0.53 0.74 
Antidepressant 0 2 0.20 0.42 
Mood stabilizer/ anticonvulsant 0 5 0.73 1.1 
Antianxiety 0 5 0.94 1.2 
ADHD 0 0 0 0 
Note: n=120 
Table 18 
Descriptive Statistic for Psychotropic Medication Classes in the First Community Assessment 
Community 
Psychotropic class Min Max M (SD) 
Antipsychotic 0 4 0.57 0.8 
Antidepressant 0 3 0.34 0.62 
Mood stabilizer/ anticonvulsant 0 4 0.78 1 
Antianxiety 0 3 0.52 0.77 
ADHD 0 0.03 0.12 
Note n=120 
Combinations of Psychotropic Medications 
Table 19 presents results on the most utilized combinations of psychotropic n1edications. 
The lTIOst frequent combination in the facility among 17 (14.20/0) participants is the antipsychotic + 
mood stabilizer / anticonvulsant + antianxiety combination. Only 9 participants (7.5%) used this 
combination of classes in the community. In addition, 10 participants (8.3%) were taking a different 
combination of psychotropic n1edications, namely mood stabilizer / anticonvulsant + antianxiety 
medication. The least likely con1bination used within the facility is antipsychotic + antidepressant 
combination (0.8 0/0) and the antipsychotic + antidepressant + mood stabilizer / anticonvulsant 
combination (0.8%). 
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Table 19 
Prevalence of Psychotropic Medication Combinations 
Combinations 
Antidepressant + antianxiety 
Antidepressant + mood stabilizer / anticonvulsant 
Antidepressant + mood stabilizer / anticonvulsant + antianxiety 
Antipsychotic + Antianxiety 
Antipsychotic + antidepressant 
Antipsychotic + antidepressant + antianxiety 
Antipsychotic + antidepressant +mood stabilizer / anticonvulsant + 
antianxiety 
Antipsychotic + mood stabilizer / anticonvulsant + AD HD 
Antipsychotic +antidepressant + ,mood stabilizer / anticonvulsant 
Antipsychotic + mood -stabilizer / anticonvulsant + antianxiety 
Antipsychotic + mood stabilizer / anticonvulsant 
Mood stabilizer / anticonvulsant + antianxiety 
Facility Community 
% (n) % (n) 
2.5 (3) 5.8 (7) 
0.0 (0) 2.5 (3) 
3.3 (4) 0.0 (0) 
5.8 (7) 5 (6) 
.8 (1) 5.8 (7) 
6.7 (8) 6.7 (8) 
2.5 (3) 4.2 (5) 
0.0 (0) 0.8 (1) 
.8 (1) 3.3 (4) 
14.2 (17) 7.5 (9) 
5 (6) 10 (12) 
8.3 (10) 5.8 (7) 
Note. This chart only includes combinations of psychotropic medications not the prevalence of participants using 
individual medications. 
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The results indicate that 12 participants (10%) were taking antipsychotic + mood stabilizer / 
anticonvulsant medications. Following this, the second most frequent combination was the 
antipsychotic + mood stabilizer / anticonvulsant + antianxiety medication, where 9 (7.50/0) 
participants were prescribed it. The least frequent conlbination used by participants in the 
community was the antipsychotic + mood stabilizer / anticonvulsant + ADHD medications. No 
participants in the facility used a psychotropic medication within the ADHD class, as a result of this, 
the sample size was too small to perfonn any statistical tests. 
Combinations that stayed consistent across group are the antipsychotic + antidepressants + 
antianxiety combinations where 8 (6.7%) participants were prescribed that combination in both 
settings. 
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Mental Health Diagnoses and Contact with Health and Mental Health Supports 
The percentage of participants with a mental health diagnosis is shown in Figure 2. 
Although there appears to be slight differences regarding anxiety, mood and cognitive challenges 
(deliriunl dementia and amnesia) across settings, none of these trends is statistically significant 
(cognitive disorder, X2 McNemar= .57, dj=l,p = .45, schizophrenia X2 McNemar= 0, dj=l,p = 
1.00, mood disorder X2 McNemar= 0, df=l,p = 1.00, or an anxiety disorder X2 McNemar= 1.33, df 
=I,p = .25). 
Anxiety disorder 
Mood disorder 
Schizophrenia 
Cognitive 
o 5 )0 15 20 25 30 
II community 
iii factility 
Figure 2. Mental Health Diagnoses at Last Facility and First Community Assessment 
A summary of participants' contact with health and mental health supports is reported in 
Table 20. 91.7% of participants in the facility and community had a physical within the last year. 
More participants in the community (91.70/0) had a physician review their medication than in the 
community (80.70/0). Significantly more participants in the community (70.7%) had seen a 
physician in the last three months than in the community (450/0) (X2 McNemar = 13.8, df= I, 
p=.OO). Participants in the community (18.3%) had significantly more contact (X2 McNemar = 4.0, 
dj= I, p=.046) with a mental health worker during the past three months than participants in the 
facility (9.2%). A mental health worker may be a psychiatrist, psychologist, social worker etc. 
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More participants in the facility (31.7%) had a behaviour program within the past 3 tllonths than in 
the community (22.5%). 
Table 20 
Contact with Professionals 
Contact with professionals 
Physical exam in the past 12 months 
Physician reviewed whole med package in past 6 months 
Visit with a physician in the past 3 months 
Visit with a mental health worker in the past 3 months 
Behaviour management PROGRAM in the past month 
Note: one participant is missing in each item, n=119. 
Facility 
% (n) 
91.7(110) 
91.7(110) 
45 (54) 
9.2 (11) 
31.7 (38) 
Community 
0/0 (n) 
91.7(110) 
80.7 (96) 
70.8 (85) 
18.3 (22) 
22.5 (27) 
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Discussion 
Introduction 
The purpose of this study was to describe the use of psychotropic medication among 120 
participants who transitioned from facilities to community settings in Ontario. Results show that 
psychotropic medication use in the community was significantly higher than psychotropic 
medication use in the facility. There were no significant changes of the total number of 
psychotropic medications used among participants, yet there were significant differences in the 
number ofPRN's used, the number of daily medications used and the class of psychotropic 
medications used. Community settings were also associated with an increase of participants 
diagnosed with an anxiety disorder and increased contact with a physician and or mental health 
worker within the last three months. The participants included in this study were adult males and 
females with a diagnosis ofID. This adult sample is consistent with other studies published on 
psychotropic medication and de institutionalization (Clarke et ai., 1990; Robertson et ai., 2000). 
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The instruments used to describe the demographics of this sanlple were the BPI, REISS and 
SIB-R adaptive scores. The adaptive behaviours were normally distributed across the ranges of 
support need that are expected in the population with ID. Both problelll behaviours and mental 
health indicators were skewed, showing relatively low rates of symptoms at the time of 
measurement in the comnlunity, despite the high prevalence of psychotropic medication use. It is 
possible either the medication is achieving its desired effect in managing symptonls or perhaps some 
individuals remain on medications longer than necessary. These results are consistent with other 
studies (Branford, 1996). Overall there were low rates of problem behaviour as reported on the BPI. 
Yet participants did score high on the stereotypy subscales. Gowdey et ai. 1897 did comnlent that 
community settings may be less likely to tolerate behaviours such as stereotypy, where as in an 
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institution environment they may go unnoticed. On the other hand, stereotypy may be likely to go 
untreated in community settings in comparison to aggression or self-injurious behaviours (R. 
Condillac, personal communication, March 24, 2012). This may be the case with our sample as our 
results show higher rates of stereotypy than rates of challenging behaviours (aggression, SIB). 
However, there is much variability among these scores. Nevertheless, the scores are low, which 
may be evidence that our sample was receiving effective treatment. The REISS scale assesses if a 
participant has indicators of a mental health problem. A cut score of nine or above is an indication 
of the aforementioned. Twenty-seven participants possessed a cut score of 9 or above on the REISS 
scale. Alternatively, 89 participants did not reach a cut score, indicating that the severity of their 
symptOllls was not in th~ clinical range at the time of the assessment. This is a high percentage of 
individuals who did not have an indication of a dual diagnosis, given that 83% of the population 
took psychotropic medications. 
Given that the BPI and REISS were conducted during the first cOlllmunity assessment, it is 
likely that participants were taking psychotropic medications when these assessments were 
conducted. This may have caused fewer participants to achieve a cut score and more participants to 
obtain lower scores on the BPI than if participants were not taking psychotropic medications at the 
time of these assessments. Also, 62 participants in this sample have a diagnosis of epilepsy. 
Psychotropic Medication Use 
This study reports on the prevalence of psychotropic medication use in four meaningful groups: 
(l) individuals who took psychotropic medication in the facility and community; (2) individuals 
who took medication in the facility but not in the comillunity; (3) individuals who took medication 
in the community but not in the facility and (4) those who were not taking psychotropic medication 
at all. A majority of participants were in the groups with no change. However, many participants 
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started using psychotropic medication in the community but not in the facility. These results should 
be compared with caution to other studies, as many studies did not separate their participants into 
these groups. It would be interesting .for there to be further investigation into the group where 
psychotropic Inedication increased in the community and what factors accounted for this increase. 
A cross-tabulation between the REISS scores above cut-off and psychotropic medication 
groups (Table 6) demonstrate that four participants were in this category. It may be interesting to 
know if effects of the transition negatively influenced any of their mental health symptoms that may 
have resulted in the increased need for medication in the community. This is consistent with 
previously published literature. For example, Thinn et al. (1990) mentioned that some studies have 
found higher functioning individuals who regress and lower functioning individuals who show 
increased levels of adaptive and maladaptive behaviour 6-8 weeks after transition. Also, Hemming 
et al. (1981) discuss the implications of psychotropic n1edication use at four, nine, twelve and 
twenty-four months after relocation. 
In the present study, the length of time out of facility ranged between 0-6 years. The mean 
time out of the facility was 3.3 years. Thinn et al. (1990) suggested that some participants require 
an increase in night sedation 9 and 12 n10nths after transition. This study found no significant 
difference among groups regarding psychotropic medication use and their time out of the facility. 
Mean psychotropic medication use resulted in 2.01 for participants in the facility and 2.1 for 
participants in the community. These results show that medication use for participants is similar 
across settings. This data included participants who were taking psychotropic and PRN medications 
together. Including PRN's into the psychotropic medication count is different than that of Thinn et 
al. (1990) who did not include 'as needed' psychotropic Inedications in their count as they were not 
PSYCHOTROPIC MEDICATION USE 66 
given regularly. We also factored out the PRN use and reported only on daily medications; here we 
also found that daily psychotropic medication use was similar across settings. 
Significant differences were found when looking at the class of psychotropic medication 
used across settings. Participants in the community used significantly more antipsychotics and 
antidepressants than participants in the facility. Participants in the facility used significantly more 
antianxiety medications than those in the community. ADHD medications were at very low rates 
across settings and mood stabilizers /anticonvulsants did not significantly change across settings. 
PRN's in the facility were on average 50% higher than in the community. Participants used 
lorazepam most often in the facility than in the community. This may also explain why the 
antianxiety medication i~ significantly higher in the facility than in the community. Another 
interesting finding is regarding daily psychotropic medication use in the community setting. 
Participants were more often taking PRN's in the facility and taking daily medications in the 
community. 
Different patterns of use across specific medication classes were found. In particular, 
participants in the community used significantly more antipsychotics and antidepressants than 
participants in the facility, while participants in the facility used significantly more antianxiety 
medications than those in the community. It is possible that SOlne aspects of relocation and/or 
changes in routine have resulted in the medication changes. Past research has shown high rates of 
antipsychotic use in a cOlnmunity setting (Burd et ai., 1991; Lunsky & Elserafi, 2012). This raises 
questions about prescribing practices and the use of antipsychotic medications to treat challenging 
behaviour, even when it is not necessarily effective (Tyrer et ai., 2008). 
Within medication classes specific trends were found. Participants were taking more 
olanzapine and quetiapine in the community than the facility; however, rates of risperidone stayed at 
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similar rates across settings, but rates of haloperidol decreased. This shows a trend towards a 
different generation of antipsychotics. Within the antidepressants, citalopram use increased in the 
community. Antianxiety medications were the only class significantly higher in the facility than the 
community. However, participants' use oflorazepam stayed similar across settings. 
It is possible that participants experienced some difficulty with the transition or adapting to a new 
environment. This notion is consistent with the literature - Hemming et al. (1981). Quetiapine and 
olanzapine are typically used to treat schizophrenia, but data suggested that the diagnosis of 
schizophrenia did not significantly increase among participants in the community setting. Studies 
suggest that an increase in psychotropic tnedications should be associated with an increase in 
psychiatric diagnoses (Burd et al. ,' 1991). Citalopram may have been given to help participants deal 
with their anxiety. Medical professionals may have prescribed psychotropic tnedications to help 
participants deal with the transition, but may have been reluctant to diagnose until after the effects 
of the transition. 
Mental Health Diagnoses and Contact with Health and Mental Health Professionals 
Patterns regarding psychiatric diagnoses show that there were no significant 
differences regarding psychiatric diagnoses across settings. It is an interesting finding given that the 
rates of psychotropic medications are significantly higher in the community setting. In a study by 
Nottestad and Linaker (1999), diagnoses of anxiety disorder remained the same before and after 
deinstitutionalization, but diagnoses of schizophrenia increased. There may be many reasons why 
psychiatric diagnoses did not increase in the community. It may be that our participants did not fit 
the clinical profile or that they did not have access to professionals who diagnose or who felt 
comfortable diagnosing nlental health issues within this highly complex population. 
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Data showed that participants in the comnlunity saw a physician and mental health worker 
significantly more in the past three months than individuals in the facility. These may be the 
individuals whose needs become higher in the community settings, or it may be an indication of the 
intensity of community supports. Also, relatively few participants have behaviour programs in 
place, which is unusual in a community setting with participants who have complex needs or high 
rates of behaviours and/or psychotropic medication use. 
Mood stabilizers and anticonvulsants 
Our results are consistent with the literature in that it is a common finding to see mood 
stabilizers and anticonv\llsants (divalproex and carbamazepine) utilized similarly across settings 
(Fischbacher, 1987; Robertson et aI., 2000). However, Clarke et aI, (1990) did show in their study a 
higher use of antiepileptic medications in a facility setting than community-based settings. 
Combinations of Psychotropic Medications 
In this paper, instead of using the word polypharmacy the word 'combinations' is used. The 
word polypharmacy has many definitions in the literature and in many cases negative connotations. 
The word 'combinations' is a neutral term that describes more than one class of medication 
prescribed. Each setting had a different combination of psychotropic medication most often utilized 
by participants. In particular, the most common combination in the facility was the antipsychotic + 
mood stabilizer I anticonvulsant + antianxiety, and the most common combination in the community 
was the antipsychotic + mood stabilizer I anticonvulsant. It is expected that mood stabilizers would 
be prevalent in both combinations as it is one of the only classes not to change over time. There 
was another small set of participants taking antipsychotic + antidepressant + mood stabilizer I 
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antipsychotic + antianxiety. The number of participants taking this combination increased by 680/0 
in the community. This is most concerning as it is the combination of medications with the most 
classes of psychotropic medications in it. A possible explanation for this Inay be that the persons 
taking these combinations may be the same participants who have an increased diagnosis of an 
anxiety disorder andlor participants who scored above cut score on the REISS. These may be the 
individuals who found it especially difficult to transition. 
Limitations 
A limitation of the present study is regarding the sample size. While a sample of 120 
participants taking psycbotropic medication is a good sample size, any analyses that grouped 
participants (e.g., participants who took psychotropic medication in both settings, participants who 
took medication in neither setting) resulted in groups that were too small to run further statistical 
analyses. A larger sample size would have allowed us to do further statistical tests to look at 
between-group comparisons. 
Another limitation of the current study was in the documentation of the PRN medication on 
the interRAI. One codes the use of a PRN only if it has been used within the last three days. This 
may mean that the PRN count was higher for participants than was cited using the interRAI ID. 
Also the interRAI ID has a previous version that was updated in 2006. This new version 
contains a section that inquires about epilepsy diagnosis and treatment. The 2005 version of the 
interRAI ID does not inquire about the treatment of epilepsy, only the diagnosis. Given that some 
participants used the 2005 interRAI ID, this study is unable to compare results regarding the 
treatment of epilepsy, which would have provided some clarification on whether the medication was 
prescribed to treat seizures, problem behaviour, or both. 
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The final limitation noted is the barrier with using the National Institute of Mental Health 
medication list. While it is a user-friendly list, it is not a comprehensive list of psychotropic 
medications. Medications were added to the list based on additional psychotropic Inedications 
occurring in the data set, and guidance was sought from skilled medical professionals to ensure 
accurate classification. A thorough list would have been preferable. 
Strengths 
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This study is one of the only and most recent Canadian studies to look at psychotropic 
medication among individuals who have been relocated. There is a paucity of research using a 
longitudinal design when looking 'at psychotropic medication use and individuals with ID who have 
relocated. Therefore, a main strength of this study is in its research design. 
. This study provides useful information regarding prescribing practices in Ontario, common 
psychotropic medications used in Canada and information that may be of interest to medical teams 
practicing in this field. This study could be used to help inform growing services in Ontario, as 
there has been a lot of capacity built helping individuals who have been relocated to settle in 
Ontario. To further inform best practices in Ontario, this study may also serve as a basis for other 
studies to be conducted in Ontario regarding deinstitutionalization and psychotropic medication. 
Evidence from this study facilitates the ability to compare some results to other studies 
conducted locally and abroad, especially since there have been inconsistent findings in the literature 
when looking at psychotropic medications across facility and community settings. This study adds 
to the growing body of research in this area. 
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Future research 
Future research should serve to replicate this study with a greater sample size. An 
investigation into more information regarding the participants who started using psychotropic 
medication in the community may be fruitful in learning about the factors regarding medication use 
during transitions from a facility to a community-based setting. PRN medications should be 
included into the study, but analyses should also factor them out so the sample can be compared 
with and without thenl. 
Building upon this research, it may help to know more information about the doses of 
psychotropic nledications, diagnoses of these participants and why particular medications were 
prescribed. This is particularly important because many psychotropic medications are often used to 
inappropriately manage behaviour. Within the context of the present study, little inlplications can 
be gleaned regarding the appropriate or inappropriate use of psychotropic medications for this 
population. McGillivray and McCabe (2005) comment that physicians and psychiatrists may have 
different prescribing practices based on different environments (facility, community, respite options, 
family homes). For example, community-based physicians and psychiatrists may be less likely to 
prescribe antipsychotics than physicians and psychiatrists working in the community. The findings 
in this study do show different classes of medications associated with each environment. 
Prescribing practices may also differ within the country the research is conducted in. This may be 
another interesting area to investigate. 
Summary and Conclusions 
Overall, there were more people taking psychotropic medication in the community compared 
to the facility. However, there were no significant differences found in the total number of 
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psychotropic medication used. Significant differences and interesting findings were found in regard 
to class, combinations, PRN use and service utilization among these 120 individuals with ID. Little 
research has been conducted using a longitudinal design when looking at psychotropic medication 
among individuals who have been relocated. Therefore, this study should provide good c01l1pliment 
to the already existing literature by providing stepping stones to further investigations. These 
investigations go hand in hand with the many research projects, clinical services, networks of care 
and guidelines that have been established to help with providing best practice services to individuals 
who have been relocated in Ontario. 
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